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Abstract: There is a pressing need for long-term neuroprotective and neuroregenerative 
therapies to promote full function recovery of injuries in the human nervous system 
resulting from trauma, stroke or degenerative diseases. Although cell-based therapies are 
promising in supporting repair and regeneration, direct introduction to the injury site is 
plagued by problems such as low transplanted cell survival rate, limited graft integration, 
immunorejection, and tumor formation. Neural tissue engineering offers an integrative  
and multifaceted approach to tackle these complex neurological disorders. Synergistic 
therapeutic effects can be obtained from combining customized biomaterial scaffolds with 
cell-based therapies. Current scaffold-facilitated cell transplantation strategies aim to achieve 
structural and functional rescue via offering a three-dimensional permissive and instructive 
environment for sustainable neuroactive factor production for prolonged periods and/or cell 
replacement at the target site. In this review, we intend to highlight important considerations 
in biomaterial selection and to review major biodegradable or non-biodegradable scaffolds 
used for cell transplantation to the central and peripheral nervous system in preclinical  
and clinical trials. Expanded knowledge in biomaterial properties and their prolonged 
interaction with transplanted and host cells have greatly expanded the possibilities for 
designing suitable carrier systems and the potential of cell therapies in the nervous system. 
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1. Introduction 
Neurodegeneration resulting from trauma, stroke, or neurological diseases causes persistent and 
progressive loss of neuronal subtype, leading to permanent structural damage and functional 
impairment. Neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), 
Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), stroke, traumatic brain injury (TBI), 
spinal cord injury (SCI), retinal degeneration, and peripheral nerve trauma are amongst the most 
debilitating conditions of the current century. They impact on the entire age spectrum worldwide, 
causing prolonged reduction in the quality of life and creating heavy psychological and financial burden. 
Scaffold-facilitated cell-based therapies are currently active areas of research in treating neural 
injuries resulting from trauma or disease. This review seeks to discuss the current state of the 
development of biomaterials served as cell-carrying scaffolds. Firstly, current challenges and emerging 
therapeutic strategies in repairing and regenerating the Peripheral Nervous System (PNS) and the 
Central Nervous System (CNS) are described, followed by the discussion of different approaches 
adopted in cell-based therapies. Then, the requirements for selecting desirable scaffolds are set out. 
Furthermore, present development states and applications of various scaffolding biomaterials are 
discussed. Lastly, conclusions and perspectives are presented for future work in developing scaffolds 
for treating neural disorders. 
1.1. Current Challenges 
In contrary to previous beliefs, neurons in both the PNS and the CNS demonstrate intrinsic abilities 
to regenerate under growth-supporting conditions. Aguayo and colleagues showed that CNS retinal 
neurons are able to regenerate within peripheral nerve grafts, but not beyond the graft into the CNS 
tissue [1]. However, due to the dissimilar post-injury physiological responses and associated glial cell 
functions, the local injury environment is permissive in the PNS yet inhibitory in the CNS. In the 
presence of nutrients, orientation, neurotrophic factors and myelin-digesting support provided by 
Schwann cells (SCs), regeneration of PNS neurons can take place spontaneously across a small nerve 
defect or be facilitated by direct end-to-end surgical reconnection. For larger nerve defects, the clinical 
golden standard, autologous nerve graft, is applied. However, nerve autografts are plagued by 
complications such as neuroma, donor site morbidity, nerve site mismatch and limited sources of 
donor tissue [2]. Complete functional recovery can rarely be achieved. Although axonal regeneration 
occurs, functional recovery may not always be the ultimate clinical outcome due to misdirection of 
regenerating axons towards an inappropriate target [3]. Therefore, there is interest in developing grafts 
with better functionalities as alternatives to autografts. 
Nerve regeneration in the CNS is even more challenging. In response to the direct damage to the 
spinal cord, a cascade of secondary injury events that further expands the zone of cell death and tissue 
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damage occurs. This leads to cell death via apoptosis and the establishment of barriers to regeneration. 
Destructive inflammation activates astrocytes and microglia, glial cells of the CNS, to proliferate and 
form glial scar in order to minimize further damage around the zone of necrotic cell death and protect 
uninjured tissue. The glial scar contains axonal growth inhibitory factors such as chondroitin sulfate 
proteoglycan and myelin-associated glycoproteins that limits axonal regeneration [4]. Most current 
therapies for the brain and the spinal cord are designed to pharmacologically modify disease symptoms 
but do not promote neural tissue repair or restoration of severed axonal connection. Trophic factors,  
anti-apoptotic drugs or anti-inflammatory drugs have been administered to limit the extent of secondary 
injury and to enhance the plasticity of undamaged circuits [5–7], however, their access to lesions in the 
CNS is often limited by numerous protective barriers surrounding the CNS, including the boney 
structures as well as the blood-brain-barrier and the blood-spinal cord-barrier [8]. Although drug 
administration via direct local injection can bypass the barriers, it leads to tissue damage. As for drugs 
that are able to cross the vascular barriers, the high doses required for systemic delivery can result  
in undesirable side effects. No therapies are yet available for full restoration of lost function over 
critical-sized nerve gaps or ongoing neurodegeneration in the PNS and the CNS [5,9]. 
1.2. Emerging Tissue-Engineering Treatment Strategies 
In the past decade, several non-cell carrying polymeric nerve guidance conduits (NGCs) have  
been approved by the USA Food and Drug Administration (FDA) and Conformit Europe (CE) for 
bridging nerve gaps and promoting peripheral neural regeneration. The current development, design 
considerations and clinical outcomes of the approved NGCs were reviewed in [2,10]. NGCs simulate the 
natural regeneration process in the PNS by providing a permissive environment for neuroregeneration, 
mainly through physical guidance cues, and have obtained clinical success for PNS treatment [4]. When 
applied to the spinal cord, NGCs increase neural sprouting as well as reduce glial scar formation and 
the invasion of immune cells [11]. Interestingly, these results are commonly observed in scaffolds with 
varying compositions and architectural features. However, therapeutic outcomes of scaffolds with 
biomaterials alone are still less desirable than autographs for long lesions. 
Tissue engineering integrates cell therapies and scaffolding technologies to replace damaged 
neurons and to reestablish the coaxial connection of neuronal circuits for functional recovery. With  
3-D scaffolds, cell survival and graft integration can be augmented in cell transplantations. Scaffolds  
also prevent the random growth of regenerating axons by providing topographical guidance. They have 
demonstrated great potential to be translated into clinical practice. The next generation of tissue-engineered 
scaffolds for clinical application is likely to be engineered with: (1) mechanical and topographical cues; 
(2) biochemical cues such as neurotrophic factors and extracellular matrix (ECM) proteins; and (3) cells 
to guide and further enhance axonal regeneration [2,12]. Cell-based therapies are particularly warranted 
in cases where the complexities of injury or disease require multifaceted regeneration strategies. Recent 
combined therapeutic approaches incorporating factors such as cells, scaffolds and biochemical cues 
applied to the CNS were reviewed in [5]. 
Two main strategies of scaffold-facilitated cell transplantation are: (1) to create a permissive 
environment for regeneration by sustained protein delivery; and (2) to replace cell or tissue loss and 
promote functional repair. One strategy to replace the functional loss due to cell or tissue damage is to 
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deliver polymer-encapsulated cells that are genetically programmed ex vivo for prolonged secretion of 
neuroactive factors. The supplement of supportive ECM components, neurotrophic factors, cell adhesion 
molecules, or anti-inflammatory cytokines promotes local cell survival and regeneration while 
attenuating secondary injury events. Cell encapsulation is particularly useful to deliver therapeutics  
that required local and controlled administration, such as neurotrophic factors with short half-lives  
and difficulties in systemic administration due to adverse side effects [13]. Cells of autogeneic, 
allogeneic and xenogeneic sources can be immunoisolated in macro- or microencapsulating devices  
with semipermeable membrane or matrix for prolonged and sustainable factor delivery in vivo. Current 
development and design considerations of cell encapsulation technology in the nervous system were 
reviewed in [13–15]. Another strategy is to seed or attach scaffolds with cells to replace supportive 
cells, neurons and other associated tissues. Cell choices, challenges and considerations for nerve tissue 
engineering [16], specifically for the brain [17], spinal cord [18] and PNS [12] were extensively 
reviewed. Most popular cell candidates include glial cells and stem/stem-like cells. Glial cells function 
to secrete neuroprotective agents that stimulate natural neural repair, whereas stem/stem-like cells have  
the additional potential to replace lost tissue via differentiating into neuronal cells. Modifying these 
cells to secrete neuroactive agents has further expanded their potential to aid repair in the nervous 
system [6]. Review of various types of adult cells used in neuroregeneration can be found in [17]. 
These scaffolds can take the form of hydrogel, macro- and microsized solid or particulate implants as 
well as pharmacologically active microcarriers (PAM) (review on PAM can be found in [19]). To date, 
numerous preclinical and clinical studies on scaffold-facilitated therapies for neurological disorders 
have demonstrated safety and efficacy. 
Through tailoring biomaterial scaffolds to suit different cell transplantation approaches and 
intended periods of application, neuroprotection and neuroregeneration efficacies of cell therapies can 
be improved. 
2. Criteria for Ideal Cell-Carriers in the Nervous System 
Biomaterial-based delivery systems are essential in augmenting the therapeutic outcomes of cell 
therapies in neural tissue engineering. Ranging from hydrogel to macro- and microsized solid 
implants, there exist many options for conveying cells into the CNS and the PNS. Different tissue  
and neurological disorders require different biomaterial designs to achieve maximal neuroprotective 
and neuroregenerative outcomes (reviewed in [12,20,21]). In general, some of the most important 
considerations for choosing appropriate biomaterials include biocompatibility and biodegradability, 
biomechanical competency as well as functionalization with instructive cues to guide neuroregeneration. 
2.1. Biocompatibility 
Selection of biocompatible biomaterials for cell-carriers is important. Biocompatibility refers to the 
ability of a biomaterial to perform and support appropriate cellular behaviors without eliciting 
undesirable responses in the host, either locally or systemically, in specific applications (cited in [19]). 
When brought in contact with host tissue, biodegradable materials and their by-products should not induce 
hemolysis and damage to other blood components, coagulation and thrombus formation, toxic side effects 
to the surroundings, tumors, foreign body reactions and immune rejections [12]. 
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2.2. Biodegradability 
Biodegradability refers to an ability of a biomaterial to degrade controllably when implanted. 
Whether a biodegradable or non-biodegradable system should be used depends on the problem being 
faced and intended application. If immunoisolation is required, as in drug delivery applications,  
non-biodegradable or slow degrading systems over the intended period of implantation are desired. 
Their scaffolds serve as physical barriers to protect the cells from the host immune system and cell or 
tissue ingrowth while allowing sustained delivery of therapeutic proteins. An additional benefit is  
their ease of retrieval. Some clinical trials reported that non-biodegradable cell-encapsulating devices 
retrieved at treatment endpoints contained viable cells inside the membrane while no cells or tissues 
were found on their outer surfaces even though the patients received no immunosuppressant [22,23]. 
On the other hand, if the delivered cells are expected to differentiate into cells at the site and replace 
lost or injured tissues and functions, biodegradable systems are necessary. In these applications,  
non-degradable systems may be unfavorable since they require secondary surgeries for removal upon 
the maturation of the regenerated nerve and are prone to long-term complications such as compression 
syndrome [2]. For systems designed to degrade with time, it is important to ensure that the scaffold 
and its by-products are well tolerated by the transplanted cells and host, and can be eliminated [17]. 
The rate of biodegradation should be tuned to match the rate of nerve regeneration [12]. For systems 
that degrade too rapidly, neuroregeneration may be hampered by inadequate protection of transplanted 
cells from invading fibrous tissue or insufficient time for nerve fibers to mature [24]. Also, they will 
lead to an elevated local concentration of degraded by-products, which may be detrimental. For 
instance, accumulation of acidic by-products of polyesters due to mismatch in hydrolysis and 
metabolized rate poses harm to the transplanted cells and host tissue. However, if the degradation rate 
is too slow, chronic compression, foreign body reactions and mild inflammatory reactions may occur 
and require secondary surgeries for removal [2,12]. Thus, it is important to optimize biodegradation 
rates of cell delivery platforms to fulfill requirements of target organs and neurological condition as 
well as duration and therapeutic goals of the intervention. 
When evaluating biodegradability, all factors contributing to scaffold degradation in native 
microenvironment should be considered. Instead of conducting simple in vitro degradability tests in 
water or phosphate buffered saline (PBS) at room temperature, assessment systems should simulate 
native degradation factors such as temperature, pH, ionic strength, hydrolysis and hence swelling, 
presence of enzymes and engulfing cells etc. 
2.3. Biomechanical Competency 
Biomechanical properties influence the performance of cell-delivery systems and subsequent 
neuroregeneration in the human body. Mechanical compliance affects cell behavior, fate and 
functioning [2]. During nerve regeneration in the PNS and the CNS, the cell-delivery systems should 
have nerve tissue matching mechanical strength to resist physiological loads and mechanical stresses 
from neighboring tissues without collapsing or losing their shape [12]. One way to obtain desirable 
mechanical properties is by combining polymers to integrate the merits of their constituents. For 
instance, blending poly(lactic-co-glycolic acid) (PLGA) with poly(L-lactic acid) (PLLA) can produce 
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scaffolds that are more flexible but can still resist extensive elongation [25]. Also, wall thickness of 
NGCs has been identified in some studies as a contributing cause of neuroma formation [2]. Thinner 
walls should be used to ameliorate the problem. To ensure safety in application as well as survival and 
proper functioning of the implants, mechanical properties of the scaffolds should be carefully designed 
and evaluated. 
Additionally, porosity and permeability are important mechanical considerations for cell-carrier 
design. Porous scaffolds or ones that become porous after gradual biodegradation in vivo allow host 
cell colonization, tissue ingrowth and vascularization [26]. These ingrowths help to minimize the 
mechanical irritation caused by relative shearing motion between the implant and host tissue [19,24]. 
Hence, necrosis and inflammation can be reduced and implants can perform with lower foreign body 
response. Moreover, vascularization of the systems allows better survival of transplanted cells and 
regenerated tissue, especially for larger-sized implants. For example, collagen guidance channels 
matrix with SC were vascularized in about a week and demonstrated the ability to support cell  
growth and proliferation after implantation [24]. Surface pores can promote host cell ingrowth at 
controlled degrees of cell spreading while allowing vasculature formation in close proximity to the  
host-material interface [19]. 
As for cell-encapsulating interventions, selective permeability of membranes or matrix is important 
in enabling the exchange of nutrient, oxygen, growth factors and metabolic products while preventing 
invasions of the host immune system. Long-term survival of the encapsulated cells and sustained 
factor delivery will be hindered if there are restrictions on the diffusive exchange of metabolic 
materials due to local reactions, such as the formation of a fibrous capsule on the implant [27]. 
Therefore, it is important to ensure that the biocompatibility, membrane thickness and properties as 
well as micro-architecture of these cell-delivery platforms are suitable for prolonged functioning [24]. 
Also, permeability of membrane should be designed to fit the specific metabolic requirements, such as 
oxygen and nutrients, of individual cell types. This is crucial especially during the initial phase of 
implantation when neovascularization is yet to occur [27]. 
2.4. Functionalization by Cues 
Neural cells are highly responsive to physical, biochemical and electrical cues present in their 
microenvironment during growth, development and regeneration stages. Functionalization of 
biomaterials can artificially recreate the spatial and temporal presentation of these cues. This modifies 
the functions of scaffolds in promoting cell viability, directing cellular activities and instructing the 
neuroregeneration process. 
Besides axonal outgrowth, the reestablishment of axonal connections is the key to successful 
functional recovery. Improved directional guidance can be achieved by incorporating physical cues in 
the scaffold design, which include bio-mimicking topographic cues and mechanical cues. Topographical 
cues include tailored surface patterning, such as nano- and microsized aligned fibers, grooves and 
pillars, as well as construct geometry, size etc. [28–33], (reviewed in [34]). Electrospinning [31,35–38], 
tethering of self-aligned polymeric scaffolds [39,40], photopolymerization [32], photocuring [33], and 
multi-channeled construction [41–44] are some of the promising ways to apply aligned features to 
scaffolds. Common 3-D scaffold processing techniques were reviewed in [45]. Mechanical properties 
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such as scaffold stiffness [33,46], elasticity [47], pore structure [43,48,49], and tension [50,51] are also 
important considerations in cell-carrier design. Many studies demonstrated the effects of physical cues 
on regulating cellular attachment, alignment, migration, growth, gene expression, and differentiation 
lineage as well as limiting the random growth of regenerated axons [7,17]. Some in vitro studies 
reported that a higher fraction of neural stem/progenitor cells was committed to neuronal lineage when 
co-stimulated by biochemical differentiation cues and scaffolds with axially aligned features [52,53]. 
NGCs with micro-patterned inner lumens were able to influence transplanted cell alignment and 
neuroregeneration across sciatic nerve defects [28,29]. Aligned scaffolds enhanced neuronal 
alignments [31] and SC alignments [32,36,37,54] as well as axonal regeneration [39,40]. 
As for biochemical cues, surface modifications with neuroactive factors, ECM molecules, adhesive 
peptides, or other specific chemical structures that closely mimic endogenous materials are employed 
to enhance cell-material interaction [9,55]. For example, immobilizing the evolutionarily preserved  
cell-binding motifs Arg-Gly-Asp (RGD) or Ile-Lys-Val-Ala-Val (IKVAV) can improve cell-adhesion 
properties of the scaffold. These surface-bound biomolecules function similarly as physical 
topographic cues in modulating cell behavior, enhancing axonal regeneration and promoting more 
seamless device integration with the host tissue. Also, immobilized neurotrophic factors and drugs can 
be used to prolong drug delivery [56–58]. However, it is important to ensure that the immobilization 
process does not affect the efficacy and bioactivity of the drug [21]. Wang et al. showed that glial-cell 
derived neurotrophic factor (GDNF) protein covalently tethered onto electrospun nanofibrous scaffolds 
remained stable and promoted neural stem cell (NSC) survival and differentiation [56]. Implantation of 
the GDNF immobilized scaffold into rat brains showed an enhanced level of transplanted neural 
stem/progenitor cells survival, proliferation, migration, and neurite growth [57]. 
Another approach to further enhance the robustness of cell-carrying scaffolds is to incorporate 
soluble biochemical cues. As with other cues, these diffusible signals function to influence the 
viability, differentiation and behavior of the delivered cells. Also, the factors delivered may modulate 
the host environment by encouraging and accelerating the process of axonal regeneration, neutralizing 
local inhibitory signals, reducing inflammation, slowing scar formation and achieving better local  
cell infiltration and implant integration. Examples of common agents delivered are growth factors, 
cytokines and drugs such as anti-inflammatory dexamethasone and α-melanocyte stimulating hormone, 
or agents that prevent scar formation such as chondroitinase ABC (chABC) and myelin-associated 
inhibition factors (reviewed in [21]). Some studies encapsulate growth factors in biodegradable 
microspheres for sustained release while modifying their surfaces with ECM components for 
conveying cells to the brain [59–65]. In another study, chABC and cells were delivered in a  
non-biodegradable NGC to reduce inhibitory cues of scar tissue. The conduit was able to provide an 
environment for cell regeneration, enabled regenerated axons to leave the implant and improved the 
morphological and functional recovery in rats with SCI [66]. For soluble biochemical cues, the most 
common way of drug delivery is through mixing target drug with scaffold precursors during 
manufacturing processes, followed by scaffold degradation and drug diffusion after implantation. To 
achieve prolonged release, drugs are sometimes encapsulated within cross-linked hydrogels, 
microparticles, micro- or nanofibers, and even firstly entrapped in microspheres and then into other 
scaffolding materials [67]. The drug delivery rate and profile can be controlled by manipulating the 
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physical properties of the biomaterials, such as pore size or cross-linking density and the design of  
the system. 
Also, these adhesion molecules and soluble factors can be incorporated into biomaterial scaffolds in 
an isotropic or anisotropic manner, meaning that they are either uniformly distributed or directionally 
oriented. Although most biochemical cues have been presented uniformly in vivo, studies showed that 
axonal regeneration via anisotropic presentation of therapeutics was more effective than isotropic 
arrangements [68]. When compared with isotropic concentrations, biomolecules in gradients promote 
better growth cone chemotaxis and are more effective in directing axonal regeneration towards the 
distal direction [2,68]. Dodla et al. showed that NGCs with gradients of nerve growth factor (NGF) 
and laminin were able to promote neuroregeneration and functional rescue better than isotropic 
controls [69]. These anisotropic NGCs were reported to be able to match the performance of autograft 
over large peripheral nerve defects of 20 mm in rats. Other parameters to consider when designing 
anisotropic scaffolds include steepness of gradient, range of drug concentrations and drug candidates 
suitable for individual nerve types and sites of injury [67]. 
Electrical stimulation can be used to influence cellular growth and differentiation for 
neuroregenerative purposes. In one study, choroid plexus (CP) cells in combination with chronic 
electrical stimulation therapy resulted in synergistic neuroprotective effects in auditory neuron rescue [70]. 
To support neuroregeneration, an ideal neural scaffold should be electrical conductive. Electroactive 
conducting polymers such as polypyrrole, polyaniline and carbon nanotubes can support cell survival, 
proliferation, differentiation as well as neurite extension, axonal regeneration and functional  
recovery [6,12,71,72] (reviewed in [73]). Other materials used to prepare neural scaffolds include 
poly(phosphoesters), polyurethanes, and piezoelectric polymers [3]. In some studies, physical and 
biochemical cues are applied to these scaffolds to improve the cell-material interactions and 
biocompatibility [38,74,75]. 
Incorporation of physical, biochemical and electrical cues in cell-carrying biomaterials enables 
researchers to fabricate interactive and instructive cell-carriers that fit desired therapeutic targets  
and strategies. 
3. Cell-Carriers with Non-Biodegradable Materials 
Common non-biodegradable cell-carriers in neural tissue engineering include silicone, polyvinyl 
alcohol (PVA) and copolymer poly(acrylonitrile-co-vinyl chloride) (P(AN/VC)), polysulphone (PSU) 
and poly(ethersulphone) (PES), poly(ethylene terephthalate) (PET) and polypropylene (PP) (Table 1). 
Although they are able to demonstrate stability over prolonged in vivo applications, their 
regeneration-inducing ability has been concluded to be inadequate when used alone [76]. In order to 
enhance their neuroregenerative properties, attempts have been made to incorporate cell supporting 
scaffolds and cells that are genetically modified and/or intrinsically able to secrete growth factors and 
therapeutic agents. Currently, the main applications of non-biodegradable materials include guidance 
channels as well as retrievable and semipermeable macroencapsulation devices for CNS applications. 
  
Int. J. Mol. Sci. 2014, 15 10677 
 
 
3.1. Silicone 
Since 1960s, silicone has been used as an inert and impermeable NGC to facilitate nerve 
regeneration following peripheral nerve and SCI. Silicone NGCs have provided an isolated 
environment impermeable to large molecules and ingrowth of scar tissue-forming cells while holding 
open a space through which regenerating cells and axons could grow [7,77]. However, early studies 
with empty or saline-filled conduits have only resulted in minimal nerve repair over distances up to  
10 mm [3]. Also, they were plagued by chronic foreign body reaction that led the formation of fibrous 
scar tissue around the implants. Currently, silicone is mainly utilized as an experimental model for 
tubulization in peripheral nerve repair studies. 
In order to induce neuroregeneration across large defects using silicone NGCs, various studies have 
incorporated cells into the conduits and functionalized the NGCs with natural biomaterials [76,78–80] 
(Table 1A). Neural progenitor cells (NPCs) [76], bone marrow mesenchymal stem cells (MSCs) [79,80] 
as well as SCs with or without modified neurotrophic factor expressions [78,81–83] have been applied 
to silicone conduits and transplanted across sciatic nerve defects in rats. Morphological regeneration 
and recovery in sensory and motor functions were observed in most cases when compared to control 
groups without cells. Also, multipotency of NPCs was maintained in these NGCs [76]. However,  
the issue of compression syndrome, which required secondary surgeries for removal, is yet to be  
addressed [2,84]. As a result, the focus of cell-carrying NGCs for spinal cord and peripheral nerve 
applications has been shifted to semipermeable or biodegradable materials. 
3.2. Polyvinyl Alcohol (PVA) and Poly(acrylonitrile-co-vinyl chloride) (P(AN/VC)) 
Currently, the only commercially available non-biodegradable NGC scaffolds with FDA and/or CE 
approval is composed of PVA, named Salubridge™ and SaluTunnel™ from SaluMedica™ L.L.C. 
(Atlanta, USA). However, there has been no information about the repair and regeneration 
performance of the devices reported in peer-reviewed journals [2,10]. 
Retrievable implants with GDNF-expressing cells in PVA matrix with PES membrane, were 
applied in rat and non-human primate PD models and promoted neuroregeneration [85,86]  
(Table 1B). No major deleterious effects or inflammatory responses were induced by the multiple 
implantations of capsules into the same intraventricular/ periventricular space in attempt to increase 
the amount of GDNF delivered [86]. 
The most commonly applied co-polymer of PVA for cell encapsulation in neural tissue engineering 
is P(AN/VC) (Table 1C). Cell-encapsulating devices with semipermeable P(AN/VC) membrane has 
been used in AD, HD, PD and chronic pain studies. A range of cells, including genetically modified 
fibroblasts that expressed neurotrophic factors like NGF and ciliary neurotrophic factor (CNTF) [87–92] 
and dopaminergic cells such as pheochromocytoma (PC12) cells [93] and chromaffin cells [23,94] 
have been encapsulated. These cells were often suspended in a hydrogel matrix of collagen, alginate or 
Matrigel®. Prolonged implantation of these devices attenuated the neural damage induced and 
promoted behavioral rescue in rats and non-human primates of different neurological disorders. One 
study showed that when a P(AN/VC) macroencapsulated implant with PC12 cells was retrieved after 
extended implantation, functional levels of Parkinsonian rats returned to that of pre-implantation, 
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demonstrating the therapeutic effects of these cells [93]. P(AN/VC) devices have showed to be  
well tolerated in vivo without showing adverse effects associated with direct systemic administration 
of neurotrophic factors. Upon retrieval, devices with asymmetric hollow fibers of P(AN/VC) and  
cell-seeded collagen matrix revealed numerous viable and mitotically active fibroblasts evenly 
distributed at high densities [87,88,92]. However, there was a general decrease in neurotrophic factor 
levels after prolonged implantation when compared with pre-implantation levels in these studies. In a 
Phase I clinical trial of chronic pain, a P(AN/VC)-coated alginate implant with xenogeneic chromaffin 
cells was applied to seven patients for about 1.5 to 6 months [23]. Although some improvements in 
pain rating and reductions in morphine intake were reported, the study did not control for placebo 
effects. Nevertheless, the device was retrievable and no host cells or fibrous coating on the surface of 
the implant in the absence of immunosuppressant was detected. In another study with P(AN/VC) 
conduits, combined drug and cell therapy of chABC, SCs and olfactory ensheathing glial cells showed 
their additive effects on and locomotory improvements in a rat SCI model [66]. 
3.3. Polysulphone (PSU) and Poly(ethersulphone) (PES) 
Polysulfones are biocompatible and stable materials applied in cell encapsulation for CNS neural 
tissue engineering (Table 1D). Permeable PSU hollow fiber-based membranes have been used for 
encapsulating genetically modified fibroblasts that expressed neurotrophic factors, such as GDNF and 
brain-derived neurotrophic factor (BDNF). These implants showed neuroprotective and functional 
recovery effects in rat models of PD [95,96], stroke [97] and epilepsy [98]. Continuous neurotrophic 
factor delivery of the device was achievable for at least six months in vivo [96]. Although a few 
microglias and white blood cells were reported around the capsules, the immunoreactions were 
negligible and the devices were well tolerated [96,97]. 
A more commonly studied member of the family is PES (Table 1E). Cell-encapsulating PES 
devices have been applied in form of a hollow fiber-based membrane with cells delivered in empty [99], 
collagen-filled [22,100–102], PVA-filled [85,86] or PET yarn-filled [103–107] matrix. PES scaffold of 
the simplest macroencapsulating configuration has been applied to the hippocampus of a rat model  
of epilepsy [99]. A GDNF-expressing human cell line was encapsulated in a semipermeable PES 
membrane and achieved suppression in recurrent generalized seizures. Despite poor encapsulated cell 
survival in some of the devices, such cell death and subsequent lowered GDNF levels did not result in 
further host cell death and inflammation when compared with control groups. Death of encapsulated 
cells may explain the various degrees of glial scar formed around the implant, restricting material 
exchange of the entrapped cells with the host environment. 
On the other hand, scaffolds with collagen fillers have been applied in various preclinical and 
clinical CNS neural disorder models. Genetically modified myoblasts that expressed CNTF were able 
to survive and remained functional after 3 months of implantation in rats with facial nerve axotomy [100]. 
Despite prolonged implantation in oxygen and nutrient straining environment, no accumulation of cell 
debris was observed in the retrieved implants. In a Phase I clinical study on ALS, a 5-cm-long implant 
of CNTF-expressing xenogeneic fibroblasts was introduced in the spinal cord of 6 ALS patients 
intrathecally with no immunosuppressant [22]. After 17 weeks of implantation, the extracted device 
remained intact with viable cells encapsulated. The outer surface was devoid of tissue and cell 
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adhesion. In another 2-year Phase I clinical study, a similar device of 2.5-cm-long was implanted into 
6 patients with HD [101,102]. Improvement in electrophysiological results was correlated with the 
amount of CNTF secreted from the implant. Although the retrievable implant remained intact and was 
well tolerated after prolonged application in vivo, the frequent replacement of the device every  
6 months limited its practical use for chronic neurodegenerative diseases. Also, variations in in vivo 
CNTF levels and cell viability between the patients were reported in these studies. The authors 
speculated that fibroblast cell death was due to reduction of the inner volume of the implant. The 
reasons for such reduction were the occurrence of cell death and the presence of necrotic debris under 
oxygen- and nutrient-strained conditions with continuous cell proliferation. Moreover, the difference 
in cell number may be attributed to differential residence time in vitro [22]. These studies demonstrated 
the importance of cell selection for practical application. 
Another design of PES implants involving a PET internal scaffold has been applied to tackle 
chronic retinal disease in various preclinical and clinical trials. The safety, drug release profile and 
efficacy has been studied in rat and canine models of retinal degeneration [103], a rabbit model [104] 
as well as human patients with retinitis pigmentosa (RP) [105,106,107], geographic atrophy (GA) 
associated with dry age-related macular degeneration [108] and Usher syndrome type 2 [106]. In these 
studies, CNTF-secreting human retinal pigment epithelium cells (RPE cells) were seeded in a scaffold 
of PET yarn and macroencapsulated by PES membrane. As the preclinical studies demonstrated a 
continuous production CNTF output of up to 1 year at therapeutic levels [104] and neuroprotective 
results in various animal models [103], a 6-month Phase I clinical study of the CNTF-producing 
Renexus® (NT-501) device (Neurotech Pharmaceuticals, Inc., Lincoln, NE, USA) was carried out on 
10 patients with advanced RP [105]. The implants were well tolerated with no severe ocular 
inflammation detected, despite one reported case of surgically-induced choroidal detachment. Cell 
populations in the implant at the end of the study remained healthy. 
After demonstrating the safety and feasibility of NT-501 for extended implantations, two follow-up 
studies supported by Neurotech Pharmaceuticals, Inc. were carried out. The first was a 12-month 
Phase II trial involving 51 patients with GA [108], and the second was a Phase II longitudinal study of 
30 to 35 months recruiting two patients with RP and one with Usher syndrome type 2 [106]. NT-501 
and the implantation process were well tolerated in both studies, with no reported treatment-related or 
systemic adverse effects over 12 and 24 months of study. In GA patients, NT-501 promoted structural 
improvements in terms of higher retinal thickness and macular volume. Improvements were detectable 
as soon as 4 months after implantation in higher CNTF dosage group and were maintained throughout 
the 12-month period. Such changes were associated with stable and maintained visual functions, measured 
by mean best-corrected visual acuity change. Yet, there were no changes in electroretinogram (ERG) 
responses and visual field sensitivity in the treated eyes compared with the baseline. As for patients 
with RP, structural rescue was shown in the thickness of outer retinal layers and lower cone density 
decrease in CNTF-treated eyes than in sham-treated eyes. The cone spacing resulting from CNTF 
treatment was comparable to normal eyes studied over similar periods of time. However, there were no 
significant changes in visual function in terms of visual acuity, visual field sensitivity, or ERG 
responses over 30 months for patients in the longitudinal study [106]. Such absence of changes may  
be due to the limitations imposed by the nature of disease progression, and sensitivity limitations of 
clinical functional evaluations employed for this population of patients. As a result, the patients were 
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evaluated by a more sensitive technique called adaptive optics scanning laser ophthalmoscopy that 
targets individual cone photoreceptors. Results suggested that there might be a slowing down in the 
progression of retinal degeneration in these patients. Analysis on NT-501 explanted from patients 
demonstrated the stable performance of the implant. The device was able to maintain a stable cell 
number, cell viability and CNTF output over 2 years [107]. CNTF, anti-CNTF antibodies, and 
antibodies to the encapsulated cells were not detected in the serum of patients at all time points. Yet, 
larger sample size was warranted for both studies as well as longer study duration for evaluating the 
effect of CNTF-treatment on GA progression. Also, there was a need for higher-resolution imaging 
techniques and evaluations on more retinal locations to provide a more sensitive analysis on the effect 
of CNTF treatment in cone structures in the longitudinal study. 
3.4. Polypropylene (PP) 
PP is usually applied for macroencapsulation for CNS neural tissue engineering (Table 1F). A porous 
PP filter with encapsulated neurotrophic factor-expressing fibroblasts was applied to rodent models of 
facial nerve axotomy and progressive motor neuronopathy [109–111]. CNTF-producing implants 
yielded neuroprotective effects on motor neurons, functional rescue and increased survival time [110,111]. 
Although the implants were generally well tolerated, a small amount of fibrotic tissue growth around 
the implant was detected without cell penetration into the construct [110]. 
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Table 1. Examples of non-biodegradable cell-carriers applied in preclinical animal studies and clinical trials. 
Biomaterial Form of Scaffold 
Cell Type & Modified 
Factor Expression (if any)
Animal & Neurological 
Disorder Model 
Outcomes Ref. 
(A) Silicone 
Tubular NGC PNS  
(Hollow) SC & SC-GDNF 
Rat sciatic nerve defect  
(10 mm) 
Improved axonal regeneration, nerve conduction velocity and 
compound muscle action potential. 
[82] 
With rat plasma SC 
Rat sciatic nerve defect  
(10 mm) 
Improved axonal regeneration. [81] 
With Matrigel® SC & SC-FGF-2 isoforms 
Rat sciatic nerve defect  
(10 mm) 
Improved axonal regeneration, sensory and motor recovery. 
Different isoforms of FGF-2 exerted different effects on the 
regenerating axons. 
[78] 
With Pluronic F127 gel 
and PGA 
SC 
Nude rat sciatic nerve defect 
(10 mm) 
Constricted and limited axonal regeneration  
with some SFI improvements. 
[83] 
With collagen NPC 
Rat sciatic nerve defect  
(15 mm) 
Improved axonal regeneration with detectable action potentials. 
Part of the transplanted cells differentiated  
into SC-like supportive cells. 
[76] 
With gelatin MSC 
Rat sciatic nerve defect  
(15 mm) 
Improved axonal regeneration, ameliorated loss of gastrocnemius 
muscle mass. Enhanced walking behavior and SFI recovery. 
[79] 
With laminin-coated 
multi-walled  
chitosan insert 
MSC 
Rat sciatic nerve defect  
(10 mm) 
Improved axonal regeneration, ameliorated loss of gastrocnemius 
muscle mass and enhanced SFI recovery. 
[80] 
(B) PVA 
Porous cylindrical matrix filler of  
cell-encapsulating device 
CNS  
In PES membrane 
Fibroblast-GDNF 
Rat PD model  
(6-OHDA induced) 
Improved movement initiation and swimming performance. After 
the withdrawal of device, behavioral and morphological 
improvements were maintained until the sacrifice. 
[85] 
Myoblast-GDNF 
Non-human primate PD 
model (MPTP-induced) 
Increased volume of the cell bodies, exerted neuroprotective 
effects and achieved transient recovery of motor deficits. 
[86] 
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Table 1. Cont. 
Biomaterial Form of Scaffold 
Cell Type & Modified 
Factor Expression (if any)
Animal & Neurological 
Disorder Model 
Outcomes Ref. 
(C) P(AN/VC)
Hollow fiber-based membrane  
of cell-encapsulating device 
CNS  
(Hollow) Chromaffin cell Rat chronic pain model 
Supported transplanted cell survival. Repeatedly reduced pain 
sensitivity with nicotine stimulation. 
[94] 
With alginate Chromaffin cell 
Phase I clinical trial:  
Chronic pain patients 
Devices were retrievable. Supported transplanted cell survival 
without immunosuppressant. Yet, only moderate therapeutic 
outcomes, including morphine intake and pain ratings 
improvements, were detected in some patients. 
[23] 
With Matrigel® Fibroblast-NGF 
Rat AD model (fimbria and 
dorsal fornix aspiration) 
Ameliorated loss of septal choline acetyltransferase expression. [92] 
With collagen 
Fibroblast-NGF 
i. Rat HD model  
(QA-induced); ii. Non-human 
primate AD model (fornix 
transection or aspiration) 
Protected neurons from induced damages.  
Reduced rotational behavior in rodents. 
[87,90,91] 
Fibroblast-CNTF 
Rat and Non-human primate 
HD model (QA-induced) 
Reduced the extent of induced striatal damage. Exerted trophic 
influence on degenerating striatal neurons as well as on critical 
non-striatal regions in non-human primates. Improved rotational 
behavior but not skilled forelimb function in rodents. 
[88,89] 
PC12 
Rat PD model  
(6-OHDA induced) 
Continued presence of intrastriatal implants was required to 
maintain the reduction in rotation behavior. Device output was 
affected by the site of implantation. 
[93] 
Tubular NGC CNS 
With Matrigel® and 
release of chABC 
SC and OEG Rat SCI Model (transection) 
Improved axonal regeneration and enhanced coupling  
of forelimb and hindlimb. 
[66] 
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Table 1. Cont. 
Biomaterial Form of Scaffold 
Cell Type & Modified 
Factor Expression (if any)
Animal & Neurological 
Disorder Model 
Outcomes Ref. 
(D) PSU 
Hollow fiber-based membrane  
of cell-encapsulating device 
CNS  
(Hollow) 
Fibroblast-GDNF 
i. Rat PD model  
(6-OHDA induced)  
ii. Rat stroke model 
(hypoxia-ischemia induced) 
Ameliorated neuronal damage reduced infarct volume. Improved 
rotational behavior in PD model. 
[95–97] 
Fibroblast-BDNF 
Rat epilepsy model  
(kainic acid induced) 
Exerted neuroprotective effects with enhanced neurogenesis, 
ameliorated seizure stage and number of abnormal spikes. 
[98] 
(E) PES 
Hollow fiber-based membrane of  
cell-encapsulating device 
CNS  
(Hollow) (human cell line)-GDNF 
Rat epilepsy model 
(electrically induced) 
Suppressed recurrent generalized seizures. [99] 
With porous PVA 
matrix 
Fibroblast–GDNF 
Rat PD model  
(6-OHDA induced) 
Improved movement initiation and swimming performance. After 
the withdrawal of device, behavioral and morphological 
improvements were maintained until the sacrifice. 
[85] 
Myoblast-GDNF 
Non-human primate PD 
model (MPTP-induced) 
Increased volume of the cell bodies, exerted neuroprotective 
effects and achieved transient recovery of motor deficits. 
[86] 
With collagen 
Myoblast-CNTF 
Rat ALS model  
(facial nerve axotomy) 
Protected motor neurons from induced cell death. [100] 
Fibroblast-CNTF 
i. Phase I clinical trial: ALS 
patients; ii. Phase I clinical 
trial: HD patients 
Prolonged device implantation and CNTF delivery were well 
tolerated. There were a varying number of encapsulated cells, 
hence, CNTF levels. 
[22,101,102] 
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Table 1. Cont. 
Biomaterial Form of Scaffold 
Cell Type & Modified 
Factor Expression (if any)
Animal & Neurological 
Disorder Model 
Outcomes Ref. 
(E) PES 
With PET yarn; 
Renexus® (NT-501) 
device (Neurotech 
Pharmaceuticals, Inc.) 
RPE cell-CNTF 
i. Rat and canine retinal 
degeneration models 
(S334ter-3 and  
Rcd1 respectively);  
ii. Healthy rabbit; iii. Phase I 
clinical trial: RP patients; 
iv. Phase II clinical trial: GA 
patients; v. Phase II clinical 
trial: RP and Usher syndrome 
type 2 patients 
Supported continuous factor production, transplanted cell survival 
and exerted neuroprotective results. Well tolerated in a Phase I 
clinical study. Promoted sustainable structural and some visual 
function improvements in Phase II trials. 
[103–108] 
(F) PP 
Porous filter membrane CNS 
(Hollow) 
Fibroblast-CNTF or GDNF
Mouse ALS model 
(pmn/pmn) 
Exerted neuroprotective effects on motorneurones. CNTF 
treatment improved motor function recovery. GDNF treatment 
slowed motorneuron loss but not axonal degeneration or 
premature death of mice. 
[109,111] 
Fibroblast-CNTF 
Rat ALS model  
(facial nerve axotomy) 
Exerted neuroprotective effects on motorneurones. [110] 
Abbreviations: AD: Alzheimer’s disease, ALS: amyotrophic lateral sclerosis, BDNF: brain-derived neurotrophic factor, MSC: bone marrow mesenchymal stem cell, 
chABC: chondroitinase ABC, CNS: central nervous system, CNTF: ciliary neurotrophic factor, FGF-2: fibroblast growth factor-2, GA: geographic atrophy associated  
with dry age-related macular degeneration, GDNF: glial cell-derived neurotrophic factor, HD: Huntington’s disease, MPTP: mitochondrial complex I inhibitor  
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, NGC: nerve guidance conduit, NGF: nerve growth factor, NPC: neuronal progenitor cell, OEG: olfactory ensheathing glia, 
P(AN/VC): poly(acrylonitrile-co-vinyl chloride), PC12: pheochromocytoma cell, PD: Parkinson’s disease, PES: poly(ethersulphone), PET: poly(ethylene terephthalate), 
PGA: poly(glycolic acid), pmn: progressive motorneuronopathy, PNS: peripheral nervous system, PP: polypropylene, PSU: polysulfones, PVA: polyvinyl alcohol,  
QA: quinolinic acid, RP: retinitis pigmentosa, RPE: retinal pigment epithelium cell, SC: Schwann cell, SCI: spinal cord injury, SFI: sciatic function index,  
6-OHDA: 6-hydroxydopamine. 
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4. Cell-Carriers with Biodegradable Materials 
Synthetic and natural biodegradable materials are very attractive candidates for transplanting cells 
into the human nervous system for prolonged local factor delivery and stimulating neuroregeneration 
and tissue re-organization. As they have generally good biocompatibility and can be tailored with 
desirable degradation rate, mechanical and biochemical properties, they are actively studied for neural 
tissue engineering. Commonly used synthetic biodegradable materials include polyesters (Table 2) and 
poly(ethylene glycol). As for natural polymers, ECM-based materials and their derivatives as well as 
other naturally occurring biopolymers are promising choices to facilitate cell therapies in the CNS and 
the PNS (Table 3). 
4.1. Commercially Approved Biodegradable Nerve Conduits 
Currently, the majority of FDA and/or CE approved nerve conduits/cuffs/wraps are biodegradable [10]. 
These include collagen-based NeuraGen® and NeuraWrap™ (Integra Life Sciences Corp., Plainsboro, 
NJ, USA); NeuroMatrix™, Neuroflex™ and NeuroMend™ (Collagen Matrix, Inc., Franklin Lakes, NJ, 
USA); and RevolNerv® (Orthomed S.A.S., Lyon, France) as well as synthetic polyester-based 
Neurotube® nerve guidance (Synovis Micro Companies Alliance. Birmingham, AL, USA) and Neurolac® 
nerve guidance (Polyganics B.V., Groningen, The Netherlands). Their degradation rates range from  
3 months to 4 years. 
Experimental and clinical results showed that these conduits were able to achieve comparable or 
even more superior neuroregenerative outcomes than autografts in relatively small nerve defects [2,3]. 
However, studies suggest that some of these devices were plagued by issues such as biocompatibility, 
swelling, degradation rate, automutilation, rigidity and patient complications [2]. Also, for critical-sized 
gaps, processed nerve allograft Avance® allograft (AxoGen Inc., Alachua, FL, USA) may be a better 
choice. Up to date, limited information is available in peer-reviewed articles regarding NeuroMatrix™, 
Neuroflex™, NeuraMend™ and NeuraWrap™ [10]. The polymer constituents of these approved 
conduits are not functionalized with biochemical or physical cues or cells. Therefore, these conduits 
fulfill only the basic criteria of desirable nerve guides [10]. Cell incorporation should be one of the 
focuses when designing the next generation’s nerve implants. 
4.2. Synthetic Biomaterials 
Synthetic biomaterials are extensively explored for neural tissue engineering. Although they do not 
have the inherent bioactivity of natural materials, they are advantageous because of their tunable 
mechanical and biochemical properties. Their product uniformity and ease of scaling up for 
manufacturing and ease of modifying with biochemical, physical and electrical cues are some of the 
advantages over natural biomaterials [112]. Commonly used synthetic biodegradable cell-carriers are 
polyesters and poly(ethylene glycol) (PEG). 
4.2.1. Polyesters 
Due to their well-established in vivo biocompatibility, safety and passing of regulatory approval, 
aliphatic polyester devices are widely used in clinical settings and neural tissue engineering. Polyesters 
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are attractive materials as cell-carriers because they can be tailored with suitable surface chemistry for 
cell attachment, proliferation, and differentiation [113]. Poly(glycolic acid) (PGA), poly(lactic acid) 
(PLA) and their co-polymer poly(lactic-co-glycolic acid) (PLGA) are among the most used polyesters 
for cell delivery. The two FDA and CE approved nerve conduits, Neurotube® and Neurolac®, are 
composed of PGA and poly-DL-lactide-co-ε-caprolactone, respectively. The effectiveness of polyester 
cell-carriers for CNS and PNS applications have been extensively evaluated in many preclinical trials 
as illustrated in Table 2. 
PLA and PGA are biodegraded via hydrolyzation into metabolites lactic acid and glycolic acid and 
are eliminated by natural metabolic pathways [114]. The biodegradation rate of polyesters depends on 
hydrophobicity and degree of crystallinity. PGA has a more hydrophilic and crystalline structure than 
PLA. Thus, the typical degradation rate of PGA is in weeks while PLA is over a year [114]. PLA 
exists in two chiral forms, poly(L-lactic acid) (PLLA) and poly(D-lactic acid) (PDLA). The faster 
degrading poly(D,L-lactic acid) (PDLLA) has a more amorphous structure than PLLA or PDLA. 
Depending on the requirements of individual applications, adjusting the copolymer ratio of lactic acid 
to glycolic acid of PLGA changes their biodegrading rates that range from less than a month to several 
years. Biodegradation that is too slow is undesirable because the encasing of regenerated nerve by 
foreign material over extended periods tends to develop compression syndromes and evoke foreign 
body reaction [41,115]. However, if the implant is degraded too fast, its by-products may cause pH 
changes around the implantation site and damage donor cells and host tissue. Therefore, the tunable 
degradation rate and mechanical properties of polyesters offers potentials in developing customized 
therapies for neural tissue engineering. 
Poly(lactic acid) (PLA) and Poly(glycolic acid) (PGA) 
As PGA has a relatively short biodegradation time, it has been explored as a temporary scaffolding 
material to facilitate donor cell functioning and ultimate cell replacement (Table 2A). PGA and its 
biodegraded by-products are well tolerated and do not create toxic inflammatory reactions [116]. SC 
containing PGA scaffolds were able to support neuroregeneration without the need of supportive 
guidance tubes in nude rats with 10 mm sciatic nerve defect after 2 months of implantation [83]. Park 
et al. showed that PGA fibers were able to support NSC survival, attachment and differentiation into 
various neuronal cell types in the brain [116]. When implanted into the cavity of mice with cerebral 
palsy, PGA scaffolds functioned as a template for the gross morphology of the regenerated 
parenchyma. Implantation of the construct resulted in the regeneration of a vascularized parenchyma 
with some reconstituted anatomical connections as well as functional improvements. This study 
suggested that PGA scaffolds were able to minimize the secondary injury response of the injured 
brain, which included inflammation and scarring. 
Longer-lasting PLLA and PDLLA scaffolds have been studied as cell-seeded biodegradable nerve 
conduits (Table 2B,C). Although PLLA has good processability, its slow degradation rate may not  
be ideal for peripheral neuroregeneration [117]. On the other hand, cell-based PDLLA NGCs have 
demonstrated biocompatibility and neuroregenerative properties as conduits in the CNS and the PNS. 
Vascularization and modest structural and functional regenerations were observed 6 weeks after the 
implantation of a porous PDLLA scaffold with D15A-secreting SCs into rats with transected SCI [118]. 
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The mild regeneration reported might be correlated with the substantial cell death occurring during the 
first days and the low transplanted SC survival rate in vivo. As a result, there might not be adequate 
levels of neurotrophic factors within the scaffold to yield significant therapeutic effects. In some 
studies, combined therapeutic approaches employing cells and mechanically functionalized PDLLA 
scaffolds have enhanced neuroregeneration in rodent models. A SC-seeded PDLLA NGC with 
micropatterned inner lumen was implanted into rats with 10 mm sciatic nerve gap [29]. These NGCs 
were able to enhance the rate of recovery and functional rescue despite having a similar number and 
size of regenerated axons with control groups (without SCs and/or without micropatterning). In a 
separate study, Hsu et al. implanted a micropatterned-PDLLA conduit seeded with NSCs to bridge a 
10 mm sciatic nerve gap in rats [28]. Nerve structural regeneration and functional recovery were 
detected upon 6 weeks of implantation. 
PLGA 
PLGA is one of the most studied biomaterials for supporting cell transplantation therapies in the 
CNS and the PNS (Table 2D). Some of the currently pursued cell-based applications of PLGA include 
cell incorporated nerve conduits for the PNS and the spinal cord, as well as, microcarriers for the 
brain. They are often used in conjunction with SCs or stem/stem-like cells that are designated for cell 
replacement and growth factor delivery.  
To examine the effects of cell incorporation in PLGA scaffolds, Teng et al. implanted a 
multicomponent PLGA and PLGA-polylysine blending scaffold with NSCs into an adult rat 
hemisection SCI model [119]. The scaffold was constructed with a biodegradable, yet cell-ingrowth 
inhibitory, outer zone. The device was prepared to achieve a degradation rate of about 30 to 60 days. 
Scaffolds, either with or without cells, were able to reduce the lesion, prevent the formation of scar 
tissue and cysts as well as improve motion and sensory recovery. Although the scaffold alone can 
support neuroregeneration, such an effect was significantly augmented with the incorporation of cells. 
The study also suggested that NSC might function to provide trophic support rather than cell 
replacement as they were found undifferentiated in the spinal cord regardless of the presence  
of scaffolds. 
Other studies involving cell-containing PLGA NGCs have demonstrated functional improvements 
in animal models of peripheral nerve injury to different extents. PLGA (85:15) foam scaffolds with 
SCs showed good in vivo tolerability and gradual degradation in rats with 10 mm sciatic nerve gap 
over 12 weeks of application [115]. Although cell-seeded PLGA conduits have a lower total axon 
count than non-seeded controls, the seeded implants with glial growth factor (GGF) pretreatment 
showed a higher degree of myelination on the regenerated axons and fastest conduction velocities. In 
another study, 20 mm sciatic nerve gap in rabbits was bridged by laminin-coated and SC-seeded 
PLGA (90:10) scaffolds [120]. 8 weeks after the implantation, comparable morphological rescues in 
mid-graft, including the number of axons and area of nerve fibers, were observed in the seeded 
implants and were comparable to autografts. Shi et al. further investigated the combined effect of cell 
replacement therapy with sustained neurotrophic factor delivery [121]. NSCs and SCs were modified 
to express GDNF and infused into PLGA tubes followed by implantation into rats with facial nerve 
transections in two separate sets of experiments. The conduits degraded within approximately two 
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months after implantation. Nerve action potential amplitude, axonal area, and axonal number were 
significantly greater in both types of genetically modified cells when compared with unmodified NSCs. 
Some studies have focused on incorporating guidance cues into cell-based PLGA scaffolds to 
enhance conduit performance. Topographical patterns on PLGA-based scaffolds have been shown to 
influence neuronal migration, SC orientation and their outgrowth [31,37]. Hadlock et al. implanted a 
five-channeled scaffold with laminin-coated PLGA (85:15) foam and SCs to a 7 mm sciatic nerve gap 
in rats [41]. After 6 weeks, regenerated fibers were detectable in each of the channels. When compared 
to autograft, similar amounts but larger axonal widths of regenerated neuronal tissue were identified in 
the mid-conduit region in the seeded-PLGA group. This multi-channeled configuration was able to 
increase the surface area for SC migration, adhesion and alignment while being pliable enough to be 
bent into gentle curves for bridging gaps. However, the study did not examine the functional rescue 
following implantation. In another study, chitosan conduits with aligned PLGA fiber inserts and MSCs 
showed better axonal regeneration and functional recovery than scaffolds only when implanted across 
a large sciatic nerve gap of 60 mm in dogs and a median nerve defect of 50 mm in non-human primate 
for 12 months [122,123]. Besides mechanical cues, neuroactive factors and natural materials such as 
collagen, laminin, fibronectin and chitosan are often applied to PLGA scaffolds as biochemical cues to 
promote cell survival, attachment, proliferation and differentiation [7,124–126]. 
Enhanced mechanical flexibility and resistance to extensive elongation can be achieved by blending 
PLGA with PLLA [25] (Table 2E). The faster-degrading PLGA functions to facilitate cell ingrowth 
while the slower-degrading PLLA provides mechanical stiffness to support the scaffold [124]. The 
PLGA-PLLA matrix has been shown to support cell survival, migration and differentiation in some 
studies. Levenberg et al. showed that a PLGA-PLLA scaffold was able to support neural lineage 
differentiation of human embryonic stem cells in vitro. When treated with NGF and neurotrophin-3 
(NT-3), neural rosette-like structures as well as vascular structures were found throughout the 
scaffolds [63]. Also, in another study, a PLGA-PLLA scaffold with retinal progenitor cells showed 
much higher cell survival and overall cell yield in mice subretinal region when compared with direct 
injection of cells after 4 weeks [64]. Enhanced survival, differentiation as well as migration and 
integration of grafted cells with host retina were detected. The device was gradually degraded with 
increasing pore sizes. 
Apart from nerve conduits, PLGA-based microspheres or PAMs have sparked lots of investigations 
as a combined therapeutic approach to convey cells while providing controlled drug delivery and 
temporary scaffolding that conforms to the transplanted site. The released growth factor can modify 
the host microenvironment as well as stimulate transplanted cell survival and direct the differentiation 
of grafted cells [65]. Several PAM systems for the brain have been developed over the past decade. 
Mahoney et al. proposed a cell delivery system with surface modified PLGA (50:50) microspheres for 
conveying embryonic neurons from the rat cortex to the brain [60]. When transplanted into rats, the 
cells differentiated into cholinergic neurons. Another NGF-releasing PAM system that conveyed PC12 
cells, with PLGA (37.5:25) microspheres resulted in improvements in behavior tests in a PD rat  
model [59]. Following this success, GDNF-releasing PAMs with fetal ventral mesencephalon cells 
adhered on PLGA (37.5:25) microcarriers was developed [61]. These PAMs degraded significantly 
after 8 weeks in vitro. Rats implanted with these PAMs showed better cell survival, fiber outgrowth 
and behavioral response than controls with injection of cells alone. Also, a larger graft volume of PAM 
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was detected. In a separate study by Bible et al., PLGA (85:15) microspheres with attached NSCs were 
created [62]. In vitro studies showed that the attached cells retained their stem cell status, viability and 
ability to proliferate. Implantion of these particles into a stroke rat model without immunosuppression 
showed that they were able to fill out the lesion cavity and provide structural support for the 
transplanted cells. They integrated efficiently within host tissue forming a primitive neural tissue. 
Some cells migrated along other particles or into the surrounding tissue, while some remained on the 
PAM. Aiming to establish neovascularization within the PAM network, they have further implanted 
vascular endothelial growth factor-releasing PAM with immortalized NSCs into a rat stroke  
model [127]. Endothelial cells from the host were attracted into the primitive neural tissue and formed 
a neovasculature in some parts, whereas in other parts, these cells merely interspersed with the 
transplanted cells. Evidence of hypervascularization was detected. Another PLGA (37.5:25) carrier 
system was designed to deliver marrow-isolated adult multilineage-inducible cells (MIAMI cells), 
which are a homogeneous subpopulation of immature human mesenchymal stromal cells [128]. 
Epidermal growth factor and basic fibroblast growth factor pretreated MIAMI cells were able to 
protect Cornu Ammonis layer 1 neurons from ischemic death in ex vivo hippocampal slices and rats 
with global ischemia. 
4.2.2. Poly(ethylene glycol) (PEG) 
PEG is another class of synthetic polymers investigated for facilitated cell delivery. PEG is useful 
in minimizing the immune response following implantation due to its resistance to protein adsorption 
and cell adhesion [21]. PEG-hydrogels with varying degradation rates can be achieved by different 
cross-linking methods. To improve cell infiltration and attachment properties, PEG can be blended 
with other biopolymers or modified with sites for cell adhesion. 
In vitro studies showed that PEG was able to support neural precursor cell survival, proliferation 
and differentiation into different neural cell types [129]. Also, these cells were able to tolerate the 
ultraviolet light-induced PEG gelation process. To achieve a more uniform seeding and earlier neural 
process extensions, Namba et al. used fibrin (to be removed after PEG gelation) as a template for 
creating a network of interconnected pores [130]. With the presence of different biochemical cues, the 
neuronal compositions within the PEG hydrogel can be controlled [131]. Further in vivo investigations 
would be needed to further demonstrate its usefulness in neural tissue engineering. 
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Table 2. Examples of synthetic, biodegradable polyester cell-carriers used in vivo in preclinical studies. 
Biomaterial Form of Scaffold 
Cell Type & Modified 
Factor Expression (if any)
Animal & Neurological  
Disorder Model 
Outcomes Ref. 
(A) PGA 
Scaffold NGC PNS  
With Pluronic F127 gel SC 
Nude rat sciatic nerve defect  
(10 mm) 
Improved axonal regeneration. SFI recovery was 
comparable to autograft. 
[83] 
Scaffold with small fibers in a woven array CNS 
- NSC 
Mouse cerebral palsy model 
(hypoxic-ischemia induced) 
Scaffold filled lesion. Reduced parenchymal loss 
with regenerated meshwork of hostand  
donor-derived neurons and neo-vascularization. 
Diminished unilateral rotation. 
[116] 
(B) PLLA 
Tubular NGC PNS 
With collagen SC Rat sciatic nerve defect (12 mm) Limited axonal regeneration and SFI recovery. [117] 
(C) PDLLA 
Tubular NGC PNS/CNS 
With micropatterned inner lumen 
(non-porous) 
NSC Rat sciatic nerve defect (10 mm) 
Improved axonal regeneration, vascularization 
and SFI recovery. 
[28] 
With micropatterned inner lumen 
(porous) 
SC Rat sciatic nerve defect (10 mm) 
Improved axonal regeneration rate  
and SFI recovery. 
[29] 
With fibrin SC-D15A Rat SCI Model (transection) 
Increased vascularization but limited axonal 
regeneration response into and across the scaffold 
as well as hindlimb function recovery. 
[118] 
(D) PLGA 
Tubular NGC PNS 
(Hollow) NSC-GDNF & SC-GDNF Rat facial nerve defect (transection)
Improved axonal regeneration and  
action potential recovery. 
[121] 
With five channels & laminin 
coating (foam matrix) 
SC Rat sciatic nerve defect (7 mm) 
Improved axonal regeneration comparable to 
autograft in mid-conduit region with axonal fibers 
detectable in all channels. 
[41] 
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Table 2. Cont. 
Biomaterial Form of Scaffold 
Cell Type & Modified 
Factor Expression (if any)
Animal & Neurological  
Disorder Model 
Outcomes Ref. 
(D) PLGA 
With GGF (foam matrix) SC Rat sciatic nerve defect (10 mm) 
Improved axonal regeneration  
and conduction velocities. 
[115] 
Of PLGA membrane and fiber 
matrix, with laminin and rat tail 
glue coating 
SC Rabbit sciatic nerve defect (20 mm)
Improved axonal regeneration  
at mid-graft comparable to autografts. 
[120] 
Of chitosan conduit, with PLGA 
fiber inserts 
MSC Canine sciatic nerve defect (60 mm)
Improved axonal regeneration  
and functional recovery. 
[122] 
MSC 
Non-human primate median  
nerve defect (50 mm) 
Improved axonal regeneration  
and functional recovery. 
[123] 
Multicomponent Scaffold CNS  
PLGA and PLGA-polylysine blend, 
with two compartments 
NSC Rat SCI model (hemisection) 
Improved axonal regeneration, reduced lesion size 
and glial scarring. Improved motion  
and sensory functions. 
[119] 
PAM/ microcarrier CNS  
With NGF release and coating with 
polylysine 
Embryonic neuron from rat 
cortex 
Healthy SD Rat 
Supported transplanted cell survival  
and differentiation. 
[60] 
With NGF release and coating with 
polylysine and fibronectin-like 
synthetic molecules 
PC12 Rat PD model (6-OHDA induced) 
Supported transplanted cell differentiation and 
reduced cell death and proliferation.  
Reduced rotational behavior. 
[59] 
With GDNF release and  
polylysine coating 
FVM cell Rat PD model (6-OHDA induced) 
Improved transplanted cell survival, fiber 
outgrowth and reduced rotational behavior. 
[61] 
With allylamine deposition and 
fibronectin coating 
NSC Rat stroke model (MCAO induced)
PAM filled lesion cavity. Scaffold integrated 
efficiently within host tissue forming  
a primitive neural tissue. 
[62] 
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Table 2. Cont. 
Biomaterial Form of Scaffold 
Cell Type & Modified 
Factor Expression (if any)
Animal & Neurological  
Disorder Model 
Outcomes Ref. 
(D) PLGA 
With VEGF release  
and laminin coating 
Immortalized NSC Rat stroke model (MCAO induced)
Attracted host endothelial cells into scaffold, 
established neovasculature in some parts and 
merely interspersed with NSCs in other parts. 
Evidence of hypervascularization present. 
[127] 
With fibronectin  
and polylysine coating 
MIAMI cell 
Rat stroke model  
(global cerebral ischemia induced)
Protected neurons in Cornu Ammonis layer 1 
hippocampal region from ischemic death. 
[128] 
(E) PLGA-
PLLA 
Scaffold CNS  
PLGA and PLLA blend,  
with laminin coating 
RPC Mouse rho−/− model 
Supported transplanted cell survival, 
differentiation, migration and integration  
into host retina. 
[64] 
Abbreviations: CNS: central nervous system, GDNF: glial cell-derived neurotrophic factor, GGF: glial growth factor, FVM cell: fetal ventral mesencephalon cell, MCAO: 
middle cerebral artery occlusion, MIAMI cell: marrow-isolated adult multilineage-inducible cell, MSC: bone marrow mesanchymal stem cell, NGC: nerve guidance 
channel, NGF: nerve growth factor, NSC: neural stem cell, PAM: pharmacologically active microcarriers, PC12: pheochromocytoma cell, PD: Parkinson’s disease, 
PDLLA: poly(D,L-lactic acid), PGA: poly(glycolic acid), PLGA: poly(lactic-co-glycolic acid), PLLA: poly(L-lactic acid), PNS: peripheral nervous system, rho
−/−
 mouse: 
rhodopsin knockout mouse, RPC: retinal progenitor cell, SC: Schwann cell, SD rats: Sprague–Dawley rats, SCI: spinal cord injury, SFI: sciatic nerve index, VEGF: 
vascular endothelial growth factor, 6-OHDA: 6-hydroxydopamine. 
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4.3. Natural Biomaterials 
4.3.1. ECM Components and Their Derivatives 
Collagen 
Collagen is one of the most extensively used components of ECM for neuroregeneration. Collagen 
has excellent cell-adhesion properties. This allows long-time survival and proliferation including 
angiogenesis of cells [132]. Spontaneous contraction of collagen gel occurs in the presence of cells. 
This is due to forces generated from cytoskeletal assembly and cell movements initiated by the 
formation of stable integrin-mediated attachments between collagen fibrils and cells [40]. Gelation of 
collagen can be induced by pH change, whereas its degradation is mediated by in vivo enzymatic 
mechanisms. Cell encapsulation within collagen matrix can be achieved under mild conditions. This 
enhances the survival of entrapped cells. Mechanical and degradation properties of collagen can be 
modulated by crosslinking [133] and the concentration of collagen used [21]. However, potential 
immune response may result if cross-species transplantation takes place or impurities exist. Currently, 
collagen-based nerve conduits/cuffs/wraps with FDA and/or CE approval include NeuraGen®, 
NeuraWrap™, Neuroflex™, NeuroMatrix™ and NeuroMend™ that are composed of bovine collagen 
type I as well as RevolNerv® that is manufactured from highly purified porcine collagen type I/III. 
Collagen-based cell-delivery systems have been studied as NGCs, fillers of NGCs and  
cell-encapsulating devices, coatings, scaffolds, in situ gelation platforms and for potential PNS and 
CNS treatments (Table 3A) [22,24,39,40,48,76,87–91,93,100–102,117,132,134–137]. Collagen offers 
a permissive environment to support cell survival, attachment, proliferation and differentiation. 
Collagen culture systems supported NSCs and NPCs to differentiation into functional neuronal circuits 
in vitro [138]. Also, culturing umbilical cord blood cells in a 3-D collagen system enhanced the 
expressions of a series of neurotrophic factors [139]. Lu et al. studied the reparative effects of 
implanting a collagen type I scaffold populated with MSCs into the lesion cavity of rats with  
TBI [134,135]. MSC neuroregenerative functions were enhanced when combined with collagen 
scaffolds. In comparison with control groups with scaffolds or cells only, MSC/collagen systems 
resulted in reduced lesion volume, enhanced angiogenesis and transcallosal neural fiber length as  
well as better sensorimotor and cognitive functions. Collagen scaffolds enabled the migration of 
transplanted cells to the lesion boundary zone while maintaining them in proximity to the injured 
tissue [134]. 
In situ gelling is another possible method to deliver collagen culture systems with minimal 
invasiveness. At constant pH, collagen becomes more viscous with increasing temperature. With the 
addition of different ECM proteins, laminin/collagen type I and fibronectin/collagen type I gels had 
different gelling temperatures that were physiologically relevant [136]. Although initial NSC survival 
was poor regardless of the delivery conditions, collagen-based gels sustained the survival of the 
remaining cells and improved cognitive functions in a mouse model of TBI. Since these collagen gels 
were able to fill irregularly shaped injury cavities and offered structural support, the delivered cells 
had a wider distribution than direct cell injections. 
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Some studies have pointed out that growth cone migration and neuroregeneration can be impeded 
by the presence of collagen due to a lack of matrix alignments or concentration-dependent  
abrogation [117]. Failure to recreate the aligned architecture of native tissues can lead to scarring and 
poor restoration of mechanical properties [140]. Therefore, many studies have focused on developing 
aligned anisotropic scaffolds. Keilhoff et al. studied the neuroregenerative effects of SC-seeded 
collagen type I/III scaffolds with different configurations in a relatively large 20 mm sciatic nerve 
defect in rats [24,132]. For cell-seeded collagen tubes, unlike the hollow configuration, no 
neuroregeneration was observed in tubes with a rather irregularly oriented inner skeleton  
structure [132]. Revascularizations were faster in seeded tubes with a hollow structure than those with 
an inner skeleton [24]. Also, neuroregeneration in seeded tubes with smaller hollow lumens was better 
than those with larger ones [132]. This was probably due to closer contacts between SCs and the 
regenerating fibers. One concern raised by the study was that animals with collagen implants showed a 
tendency for automutilating their treated digits [132]. This maybe contributed by mechanical irritations 
resulting from graft rigidity and the relatively large graft volume used. In order to mimic the spatial 
and molecular phenotype of autograft, Philips et al. developed a tethered and self-aligned collagen 
type I guidance conduit to deliver SCs to the PNS [40]. Uniaxial strain generated during the 
spontaneous gelling process in the presence of fibroblasts and SCs aligned the scaffold. SCs were 
found aligning along the directed matrix. Implanting this system into rats with 5 mm sciatic nerve 
defect showed greater axonal regrowth than controls. To fabricate a more compact and tissue-like 
scaffold with self-aligned SCs within a tethered collagen I matrix, interstitial fluid was removed by 
plastic compression [39]. These implants supported axonal regeneration across a 15 mm rat sciatic 
nerve gap after 8 weeks of implantation. 
In short, collagen culture systems have great potentials in offering a generally biocompatible and 
ECM-mimicking environment for regenerating the nervous system. However, careful design and 
further in vivo investigations are needed to ensure treatment efficacy and biocompatibility of these 
potential cell-based therapies. 
Gelatin 
Gelatin is derived from denatured collagen and has been widely explored as macroencapsulating 
scaffolds and microcarriers for cell delivery to the CNS (Table 3B). The mechanical and chemical 
properties of gelatin can be modulated by covalently incorporating bioactive cues. Gelatin can also be 
mechanically stabilized by cross-linking to prevent its rapid clearance from the implanted site [3,12]. 
Gelatin has good biocompatibility and is often applied without immunosuppressant. An RPE cell 
sheet embedded into a gelatin sheet was transplanted into pigs without immunosuppression [141]. The 
gelatin-based implant was well tolerated with no observable infiltration of inflammatory cells. 
Transplanted cells were able to survive in the eye for up to 3 months and achieved some 
morphological rescue. However, sheet folding and degeneration of the inner layers of transplanted 
RPE cells were detected in some regions after prolonged implantation [141]. In another study, 
modified SCs with NT-3 production were co-cultured with differentiating NSCs modified to secrete 
tyrosine protein kinase C, a preferential binding receptor of NT-3, in a gelatin sponge and implanted 
into a rat SCI model [142]. The transplanted NSC-derived neural network integrated into the host 
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network and formed a relay to conduct signals. Improvements in voluntary movement, body weight 
support, foot placement accuracy and coordination recovery were reported. 
On top of macroencapsulating scaffolds, gelatin microcarrier systems have been evaluated in 
preclinical and clinical studies for CNS applications. Cross-linked porcine gelatin microspheres, with 
L-dopa-producing human RPE cells attached to their surfaces, were applied as a potential PD 
treatment under the name Spheramine® (Bayer Schering Pharma AG, Berlin, Germany) in these 
studies. In animal models of PD, the microspheres allowed prolonged survival and monolayer 
distribution of the attached cells in the absence of immunosuppression. Unattached RPE cells were not 
able to survive well or to produce lasting therapeutic effect in the brain [143]. Long-term functional 
improvements as well as survival of RPE cells under no immunosuppressant were also observed in rat 
and non-human primate models of PD [143–146]. However, there were indications of chronic 
inflammation in rats at 5 months [146] as well as mild astroglial cell proliferation and inflammation, 
but no evidence of granulomatous or immune-mediated reactions in non-human primates [143]. 
Positron emission tomography imaging 2 months after transplantation in non-human primates revealed 
enhanced dopamine levels [145]. Phase I clinical trial on 6 patients with advanced PD showed that the 
device was well tolerated after 2 years of implantation [143]. Improvements in Unified Parkinson 
Disease Rating Scale motor disability score was detected 12 months after implantation and was 
sustained for 48 months, except for one patient who refused to be off the PD medications overnight. 
This was followed by a 2-year Phase II trial that recruited 71 patients. However, it was halted due to 
adverse effects reported [147]. Brain autopsy findings from a subject the treatment reviewed a drastic 
drop in overall survival of transplanted RPE cells after 6 months of implantation. Also, local 
inflammatory and astrocytic reactive changes were observed within the needle tract lesions and often 
within the microcarrier matrix material. 
Laminin and Fibronectin 
Laminin is the main non-collagenous component of the basal lamina that can promote neurite 
outgrowth and guide neurite development [9,12]. Fibronectin is a glycoprotein found in blood that is 
involved in wound healing and cell-adhesion as well as in axonal development and repair [21]. Laminin 
and fibronectin interact with cells and allow cell attachment to ECM as well as further signal 
transduction [17]. They support cell proliferation, migration and differentiation. Fragments of laminin 
and fibronectin, for example, peptides IKVAV, Tyr-Ile-Gly-Ser-Arg (YIGSR) and Arg-Gly-Asp-Ser-Pro 
(RGDSP) have been isolated and used for functionalizing scaffolds [148,149]. Studies have shown  
that laminin or fibronectin-coated scaffolds, even without cells, have more superior neural regeneration 
effects than control systems (reviewed in [17]). As a result, they are often employed for functionalizing 
NGCs, microcarriers, cell encapsulating devices and scaffolds to promote cell attachment, survival and 
motility (Table 3C,D) [41,59,62,64,80,120,127,128,136,150,151]. 
Laminin and fibronectin are often incorporated into hydrogels. Fibronectin- and laminin- 
incorporated collagen gels were explored as in situ gelling cell-carriers for TBI [136,150]. The gels 
were introduced with minimal invasiveness and were able to fit to the irregularly shaped injury cavity 
to provide physical support in a rat model of TBI. Although the delivery conditions used in this study 
did not protect NSCs from the initial decline in survival, NSC survival was enhanced after 8 weeks of 
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transplantation when compared with direct injection of NSCs [136]. This study also reported that 
laminin-based scaffolds functioned better than fibronectin-based scaffolds in enhancing cell survival 
and functional recovery. In another study, the effects of fibronectin incorporation into alginate gel 
have been investigated. When fibronectin and SCs were added to the lumen of a biodegradable NGC 
filled with alginate hydrogel, these two factors showed additive effects on neuroregeneration across  
a 10 mm rat sciatic nerve gap [151]. A more significant rate of neuroregeneration and prolonged 
transplanted cell viability were observed after 6 weeks of implantation when compared with control 
conduits. Fibronectin improved the proliferation of transplanted SCs and host SCs that entered the 
NGC from the nerve stumps. 
Fibrin 
Fibrin is a key component in blood clotting and consists of a dense meshwork of cross-linked 
fibrinogen and thrombin. Its properties can be tailored by covalent modification. As with other 
naturally occurring biopolymers in the body, fibrin promotes cell adhesion with reduced immune 
response. It is explored as a filling medium for nerve conduits (Table 3E) [118,152]. 
In one study, fibrin glue with SCs or differentiated MSCs was incorporated into a biodegradable 
NGC and implanted across a 10 mm rat sciatic nerve defect [152]. The fibrin matrix was almost 
dissolved after 2 weeks with significantly better cell adherence to the NGC and cell distribution than 
those seeded in growth medium alone. A longer nerve regeneration distance was also observed in 
seeded fibrin conduits. Also, with daily injections of cyclosporine A, a fibrin NGC with fibrin filler 
was able to support the survival of MSCs, enhanced axonal regeneration and reduced immediate 
inflammation response when implanted across a rat sciatic nerve gap of 10 mm after 3 weeks  
of implantation [153]. 
Matrigel® 
Matrigel® contains a number of ECM molecules and growth factors and has been used as filler for 
nerve guidance channels of biodegradable [137,154,155] or non-biodegradable source [66,78] and 
cell-encapsulating device [92] (Table 3F). Although it had superior properties in promoting neurite 
growth and enhancing cell survival, proliferation and functioning, Matrigel® derivation from a 
sarcoma cell line source has greatly limited its potential clinical use [11]. 
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Table 3. Examples of biodegradable cell-carriers composed of Extracellular matrix components and their derivatives in preclinical animal 
studies and clinical trials. 
Biomaterial Form of Scaffold 
Cell Type & Modified 
Factor Expression (if any)
Animal & Neurological 
Disorder Model 
Outcomes Ref. 
(A) Collagen 
Scaffold in cylindrical form CNS  
Collagen I MSC 
Rat TBI model 
(controlled cortical 
impact induced) 
Reduced lesion volume, supported transplanted cell migration 
into lesion boundary zone, enhanced angiogenesis and 
improved sensorimotor cognitive functions. 
[134,135] 
Scaffold formed by in situ gelation CNS  
Collagen I with laminin or 
fibronectin 
NSC 
Mouse TBI model 
(controlled cortical 
impact induced) 
Scaffold conformed to injury cavity and supported cell 
migration into adjacent tissue. Improved cognitive function. 
[136] 
Scaffold NGC PNS  
Collagen I/III (hollow or with 
collagen inner skeleton) 
SC 
Rat sciatic nerve defect  
(20 mm) 
Neuroregeneration and revascularization were better in cell-
seeded hollow collagen tubes, especially ones with reduced 
lumen. The inner skeleton impaired nerve regeneration 
independent of whether SCs were added or not. 
[24,132] 
Collagen I (Tethered and 
uniaxially aligned) 
SC & fibroblast 
Rat sciatic nerve defect  
(5 mm) 
SC aligned along the directed matrix.  
Improved axonal regrowth. 
[40] 
Collagen I (Tethered and 
uniaxially aligned, followed by 
plastic compression) 
SC 
Rat sciatic nerve defect  
(5 mm and 15 mm) 
SC aligned along the directed matrix.  
Improved neuroregeneration across the gap. 
[39] 
With Matrigel® and daily 
injections of FK506 
SC 
Mouse sciatic nerve 
defect (6 mm) 
Improved axonal regeneration as well as functional recovery 
index in the hindpaw. 
[137] 
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Table 3. Cont. 
Biomaterial Form of Scaffold 
Cell Type & Modified 
Factor Expression (if any)
Animal & Neurological 
Disorder Model 
Outcomes Ref. 
(A) Collagen 
Scaffold  CNS  
Cross-linked collagen I (with a 
small amount of collagen III) 
with longitudinal  
pore orientation 
NSC 
Rat SCI model  
(5 mm full-resection) 
Defects had fewer cystic cavities and were filled largely with 
fibrous scars favorably aligned with the long axis of the spinal 
cord. Yet, no myelinated axon at the defect-center and 
recovery of bladder and hindlimb function were observed 
at the end of study. 
[48] 
Filler of tubular NGC PNS  
Of silicone NPC 
Rat sciatic nerve defect  
(15 mm) 
Improved axonal regeneration with detectable action 
potentials. Part of the transplanted cells differentiated into 
SC-like supportive cells. 
[76] 
Of PLLA SC 
Rat sciatic nerve defect  
(12 mm) 
Limited axonal regeneration and SFI recovery. [117] 
Filler of cell-encapsulating device with hollow-fiber  
based membrane 
CNS  
Of P(AN/VC) 
Fibroblast-NGF 
i. Rat HD model  
(QA-induced)  
ii. Non-human primate 
AD model (fornix 
transection or aspiration) 
Protected neurons from induced damages. Reduced rotational 
behavior in rodents. 
[87,90,91] 
Fibroblast-CNTF 
Rat and Non-human 
primate HD model  
(QA-induced) 
Reduced the extent of induced striatal damage. Exerted 
trophic influence on degenerating striatal neurons as well as 
on critical non-striatal regions in non-human primates. 
Improved rotational behavior but not skilled  
forelimb function in rodents. 
[88,89] 
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Table 3. Cont. 
Biomaterial Form of Scaffold 
Cell Type & Modified 
Factor Expression (if any)
Animal & Neurological 
Disorder Model 
Outcomes Ref. 
(A) Collagen 
Of P(AN/VC) PC12 
Rat PD model  
(6-OHDA induced) 
Continued presence of intrastriatal implants was required to 
maintain the reduction in rotation behavior. Device output was 
affected by the site of implantation. 
[93] 
Of PES 
Myoblast-CNTF 
Rat ALS model  
(facial nerve axotomy) 
Protected motor neurons from induced cell death. [100] 
Fibroblast-CNTF 
i. Phase I clinical trial: 
ALS patients; ii. Phase I 
clinical trial: HD patients 
Prolonged device implantation and CNTF delivery were well 
tolerated. There were a varying number of surviving cells, 
hence, CNTF levels. 
[22,101,102] 
(B) Gelatin 
Scaffold CNS  
- 
RPE cell sheet Healthy pig 
Improved axonal regeneration with no immunosuppression 
administered. Yet, sheet folding and degeneration of inner 
layers of the transplanted cells were detected at some areas. 
[141] 
SC-neurotrophin-3 &  
NSC-TrkC Co-culture 
Rat SCI model 
(transection) 
Transplanted NSC-derived neural network integrated into host 
neural networks and formed a relay to conduct signals. Improved 
voluntary movement, body weight support, accuracy of foot 
placement and coordination recovery. 
[142] 
Tubular NGC PNS  
Of gelatin/poly(ε-caprolactone) Exfoliated deciduous tooth-
derived stem cells 
Rat sciatic nerve defect  
(10 mm) 
Enhanced transplanted cell survival and promoted axonal 
regeneration. Improved SFI and sensory functional recovery. 
[156] 
Filler of tubular NGC PNS  
Of silicone MSC 
Rat sciatic nerve defect  
(15 mm) 
Improved axonal regeneration, reduced loss of gastrocnemius 
muscle weight. Enhanced walking behavior and SFI recovery.
[79] 
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Table 3. Cont. 
Biomaterial Form of Scaffold 
Cell type & Modified 
Factor Expression (if any)
Animal & Neurological 
Disorder Model 
Outcomes Ref. 
(B) Gelatin 
Microcarrier CNS  
Cross-linked  
gelatin Spheramine®  
(Bayer Schering Pharma AG) 
RPE cell 
i. Rat and non-human  
primate PD models  
(6-OHDA induced);  
ii. Phase I & II clinical 
trial: PD patients 
In animal models, PAM supported transplanted cell survival in 
the absence of immunosuppression with enhanced dopamine 
levels. Yet, there were signs of chronic inflammation and mild 
astroglial cell proliferation. In Phase I clinical trial, PAM were 
well tolerated after prolonged implantation and had improved 
Unified Parkinson Disease Rating Scale motor disability score. 
Yet, Phase II trial was halted due to adverse effects reported. 
[143–147,157] 
(C) Laminin 
Scaffold formed by in situ gelation CNS  
With Collagen I NSC 
Mouse TBI model 
(controlled cortical 
impact induced) 
Scaffold conformed to injury cavity, supported cell migration 
into adjacent tissue and improved cognitive function. 
Outcomes were more favorable than  
fibronectin-based scaffolds. 
[136] 
Filler of tubular NGC PNS  
Of PLGA conduit with  
five channels 
SC 
Rat sciatic nerve defect  
(7 mm) 
Improved axonal regeneration comparable to autograft in mid-
conduit region with axonal fibers detectable  
in all channels. 
[41] 
Of PLGA membrane and  
fiber matrix 
SC 
Rabbit sciatic nerve 
defect (20 mm) 
Improved axonal regeneration at  
mid-graft comparable to autografts. 
[120] 
Of silicone, with laminin-coated 
multi-walled chitosan insert 
MSC 
Rat sciatic nerve gap  
(10 mm) 
Improved axonal regeneration, ameliorated loss of 
gastrocnemius muscle mass and enhanced SFI recovery. 
[80] 
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Table 3. Cont. 
Biomaterial Form of Scaffold 
Cell Type & Modified 
Factor Expression (if any)
Animal & Neurological 
Disorder Model 
Outcomes Ref. 
(C) Laminin 
Coating of scaffold CNS  
Of PLGA and PLLA blend RPC Mouse rho
−/−
 model 
Supported transplanted cell survival, differentiation, migration 
and integration into host retina. 
[64] 
Coating of PAM/microcarrier CNS  
With VEGF release  
and laminin coating 
Immortalized NSC 
Rat stroke model  
(MCAO induced) 
Attracted host endothelial cells into scaffold, established 
neovasculature in some parts and merely interspersed with 
NSCs in other parts. Evidence of hypervascularization present.
[127] 
(D) Fibronectin 
Scaffold formed by in situ gelation CNS  
With Collagen I NSC 
Mouse TBI model 
(controlled cortical 
impact induced) 
Scaffold conformed to injury cavity, supported cell migration 
into adjacent tissue and improved cognitive behavior. 
Outcomes were less favorable than  
laminin-based scaffolds. 
[136,150] 
Filler of tubular NGC PNS  
Of PHB conduit, with 
fibronectin in alginate gel 
SC 
Rat sciatic nerve defect  
(10 mm) 
Improved transplanted cell survival. Supported proliferation of 
transplanted SCs and host SCs.  
Augmented axonal regeneration. 
[151] 
Coating of PAM/microcarrier CNS  
With polylysine and 
fibronectin-like synthetic 
molecules coated PLGA 
(37.5:25), and release of NGF
PC12 
Rat PD model  
(6-OHDA induced) 
Supported transplanted cell differentiation and reduced cell 
death and proliferation. Reduced rotational behavior. 
[59] 
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Table 3. Cont. 
Biomaterial Form of Scaffold 
Cell Type & Modified 
Factor Expression (if any)
Animal & Neurological 
Disorder Model 
Outcomes Ref. 
(D) Fibronectin 
With allylamine deposition and 
fibronectin coated  
PLGA (85:15) 
NSC 
Rat stroke model  
(MCAO induced) 
PAM filled lesion cavity. Scaffold integrated efficiently within 
host tissue forming a primitive neural tissue. 
[62] 
With fibronectin and polylysine
coated PLGA (37.5:25) 
MIAMI cell 
Rat stroke model  
(global cerebral  
ischemia induced) 
Protected neurons in Cornu Ammonis layer 1 hippocampal 
region from ischemic death. 
[128] 
(E) Fibrin 
Filler of tubular NGC PNS/CNS  
Of PDLLA SC-D15A 
Rat SCI Model 
(transection) 
Increased vascularization but limited axonal regeneration 
response into and across the scaffold  
as well as hindlimb function recovery. 
[118] 
Of PHB SC& differentiated MSC 
Rat sciatic nerve defect  
(10 mm) 
Improved nerve regeneration distance. [152] 
(F) Matrigel® 
Filler of tubular NGC PNS/CNS  
Of TMC-CL SC 
Rat SCI model  
(Partial transection) 
Improved axonal regeneration. [155] 
Of collagen, with daily 
injections of FK506 
SC 
Mouse sciatic nerve 
defect (6 mm) 
Improved axonal regeneration as well as functional recovery 
index in the hindpaw. 
[137] 
Of chitosan SC 
Rat sciatic nerve defect  
(12 mm) 
Improved axonal regeneration, mid-shank circumference and 
nerve conduction velocity. 
[154] 
Of silicone SC & SC-FGF-2 isoforms
Rat sciatic nerve defect  
(10 mm) 
Improved axonal regeneration, sensory and motion functional 
improvements. Different isoforms of FGF-2 exerted varying 
effects on the regenerating axons. 
[78] 
Of P(AN/VC) and  
release of chABC 
SC & OEG 
Rat SCI Model 
(transection) 
Improved axonal regeneration and  
enhanced coupling of forelimb and hindlimb. 
[66] 
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Table 3. Cont. 
Biomaterial Form of Scaffold 
Cell Type & Modified 
Factor Expression (if any)
Animal & Neurological 
Disorder Model 
Outcomes Ref. 
(F) Matrigel® 
Filler of cell-encapsulating device  
with hollow-fiber based membrane 
CNS  
Of P(AN/VC) Fibroblast-NGF 
Rat AD model  
(fimbria and dorsal  
fornix aspiration) 
Ameliorated loss of septal choline  
acetyltransferase expression. 
[92] 
Abbreviations: AD: Alzheimer’s disease, ALS: Amyotrophic lateral sclerosis, chABC: chondroitinase ABC, CNS: central nervous system, CNTF: ciliary neurotrophic 
factor, FGF-2: fibroblast growth factor-2, HD: Huntington’s disease, MCAO: middle cerebral artery occlusion, MIAMI cell: marrow-isolated adult multilineage-inducible 
cell, MSC: bone marrow mesenchymal stem cell, NGC: nerve guidance channel, NGF: nerve growth factor, NPC: neural progenitor cell, NSC: neural stem cell,  
OEG: olfactory ensheathing glia, PAM: pharmacologically active microcarriers, P(AN/VC): poly(acrylonitrile-co-vinyl chloride), PC12: pheochromocytoma cell,  
PD: Parkinson’s disease, PDLLA: Poly (D,L-lactic acid), PES: poly(ethersulphone), PHB: poly(hydroxybutyrate), PLGA: poly(lactic-co-glycolic acid), PLLA:  
poly(L-lactic acid), PNS: peripheral nervous system, QA: quinolinic acid, rho
−/−
 mouse: rhodopsin knockout mouse, RPC: retinal progenitor cell, RPE cell: retinal pigment 
epithelial cell, SC: Schwann cell, SCI: spinal cord injury, SFI: sciatic function index, TBI: traumatic brain injury, TMC-CL: trimethylene carbonate-caprolacton block 
copolymer, 6-OHDA: 6-hydroxydopamine. 
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4.3.2. Biodegradable Polymers of Non-Mammalian Origins 
Alginate 
Alginate is a biocompatible and naturally occurring polysaccharide commonly purified from brown 
algae. Purity of alginate is important in preventing undesirable host responses [14]. Gelation of 
alginate is triggered by divalent cations under physiologically relevant conditions. Degradation of 
alginate scaffolds in vivo is mainly due to the gradual exchange of gelling divalent cations with  
sodium ions. Alginate is often used as a cell encapsulation system and filler for biodegradable or  
non-biodegradable NGCs. It can form a semipermeable matrix that allows the transfer of therapeutic 
agents, gases, nutrients, and waste products between the immunoisolated cells and the host 
environment. Some targeted neurological conditions include AD [158], HD [159–161], PD [162], 
stroke or TBI [163–165], glioma [166], chronic pain [94,167] and sensory diseases [70,168] (Table 4A). 
Alginate microcapsules have been used to provide immunoisolated cell delivery to the CNS and are 
well tolerated in animal models in a range of neurological conditions. In one study, alginate 
microcapsules with endostatin-expressing modified fibroblasts were implanted into a rat glioma  
model [166]. Viable transplanted cells, maintained factor secretion and reduced tumor volume were 
detected in treated rats after 4 months of implantation. These rats survived longer than untreated rats. 
In another study, alginate microcapsules were able to support the survival of genetically modified 
MSCs that expressed neuroprotective glucagon-like peptide-1 and exert neuroprotective effects on TBI 
rats after 2 weeks of implantation [163]. Garcia et al. further demonstrated the mechanical stability of 
these carriers in a mouse AD model [158]. Alginate beads with modified CNTF-secreting myoblasts 
were found intact after 8 months of implantation and resulted in significant improvements in  
cognitive functions. 
In order to strengthen the mechanical properties of alginate scaffolds, some studies have included 
semipermeable polylysine or polyornithine coating in the alginate microcapsule design for CNS 
application. CP cells from a range of donors, including xenogeneic sources, have been encapsulated in 
these coated carriers and applied into various animal models of HD, stroke and sensory loss with 
generally good biocompatibility. One study showed that the process of serial coating and 
encapsulation did not impact cell survival [161]. Minimal gliotic reactions after 3 days of implantation 
were observed in rats receiving encapsulated CP cells when compared with the control group with 
unencapsulated ones [164]. Also, a separate study demonstrated that encapsulated CP cells remained 
metabolically active for at least 6 months post-implantation [70]. Coated-microcarriers with CP  
cells reduced striatal infarct volume of rats with stroke and resulted in motor and neurological 
improvements [164,165]. Similarly, these implants were able to reduce the lesion volume of rats [159] 
and non-human primate [161] displaying HD symptoms. Improved motor functions were detected in 
these rats. In the case of auditory neuron rescue in deafened cats, Wise et al. demonstrated that 
neuroprotective effects were most prominent when encapsulated cells were applied in combination 
with chronic electrical stimulation [70]. Other studies have applied coated carriers with chromaffin 
cells or PC12 cells to rodent models of PD and chronic pain [162,167]. They were well tolerated in 
vivo and remained intact although some were deformed probably as a result of the mechanical forces 
exerted by the host brain. Improvements in behavioral tests after prolonged implantation were detected. 
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In another study involving the encapsulation of BDNF-overexpressing SCs showed enhanced auditory 
neuron survival in deafened guinea pigs [168]. 
As alginate is biologically inert, some studies have functionalized alginate with ECM components 
to further enhance its potential as a cell transplantation matrix. An enhanced rate of axonal 
regeneration was detected when liquid fibronectin was added to the alginate matrix of a biodegradable 
NGC that was seeded with SCs [151]. 
Apart from biodegradable cell-encapsulating devices, alginate has been applied to immunoisolated 
cells in devices with semipermeable non-biodegradable outer membrane. A P(AN/VC) encapsulating 
alginate system with chromaffin cells have been applied to patients with chronic pain in a Phase I trial 
without immunosuppressant. Retrieved devices showed sustained cell survival and no fibrous coating 
on device despite moderate therapeutic outcomes after prolonged implantation [23]. 
Agarose 
Similar to alginate, agarose is a linear polysaccharide obtained from seaweed and must undergo 
extensive purification to prevent immune responses after implantation [21]. Reversible gelation of 
agarose is temperature-triggered. Agarose has been explored as a cell encapsulation system in 
preclinical studies (Table 4B). BDNF-overexpressing fibroblasts in agarose were used to coat the 
electrodes of a cochlear implant [169]. No noticeable inflammation was found surrounding the agarose 
matrix despite signs of cell migration away from the matrix in some implants. Although cell survival 
decreased over the course of implantation, the system was able to demonstrate neuroprotection on 
spiral ganglion neurons in the deafened guinea pigs after 48 days of implantation. 
Chitosan 
Chitosan is a derivative of chitin, which is widely found in crustacean shells, fungal cell walls and 
insect exoskeletons. Chitosan has similar molecular structure to glycosaminoglycan, allowing its 
interaction with ECM molecules. Gelation and degradation of chitosan are mediated by ionic or 
chemical cross-linking with glutaraldehyde and enzymatic hydrolysis respectively [19]. As chitosan 
lacks bioactivity and that pure chitosan cannot support adequate cell adhesion, it is often used in 
combination with other materials for nerve tissue engineering applications (Table 4C) [19,114]. 
Chitosan-silk fibrin wraps with adipose-derived stem cells or SCs were able to improve neurological 
and functional recovery in rats with 10 mm partial sciatic nerve defect after 24 weeks of implantation [170]. 
In other studies, cell-carrying chitosan NGCs with different biodegradable fillers, including collagen, 
Matrigel® and PLGA, and different cell types, such as SCs, MSCs and NSCs, have been applied to 
animal models of peripheral nerve defects [42,122,123,154,171]. Generally, these conduits were able 
to encourage axonal regeneration. In one study, a chitosan NGC with Matrigel® and SCs of autologous 
or MSC-derived sources was implanted across a 12 mm rat sciatic nerve defect [154]. Similar axonal 
regeneration, recovery in mid-shank circumference of hindlimbs and nerve conduction velocities were 
observed for both types of SCs and were better than PBS-filled control conduits after 3 months of 
implantation. Chitosan conduits with physical cues incorporated have been shown to enhance 
neuroregeneration [42,122,123]. Conduits with aligned PLGA inserts were able to promote better 
axonal regeneration and functional recovery than scaffold alone when implanted in dogs with a large 
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sciatic nerve gap of 60 mm [122] and non-human primates with a median nerve gap of 50 mm [123] 
after 12 months of implantation. 
Dextran 
Dextran is a bacterial-derived polysaccharide and has been applied for coating neural implants due 
to its anti-thrombotic properties as well as resistance to cell and protein adhesion [21]. In order to 
encourage cell-material interactions for tissue engineering purposes, dextran has been chemically 
modified for better cell adhesion or fabricated with porous structures to encourage tissue infiltration [172]. 
A collagen-coated dextran microcarrier (Cytodex® 3, Sigma-Aldrich, St. Louis, MI, USA) was the 
first microcarrier explored for conveying cells into the brain, reported by Cherksey et al. (Table 4D) [173]. 
When chromaffin-cell attached Cytodex® 3 microcarriers were introduced into rat PD models, these 
microcarriers were able to support prolonged cell survival at the transplanted site and resulted in more 
significant and longer-lasting behavioral improvements than direct cell injections over 8 months [173]  
and 12 months [174] of study. Enhanced survival of microcarrier attached human fetal ventral 
mesencephalic neurons after 3 months of implantation in PD rats without immunosuppressant was  
also demonstrated in another study [175]. These microcarriers were generally well tolerated with no 
inflammation when implanted in the striatum [173] despite one study, which reported a low level, yet 
ongoing glial response after 14 months of implantation [174]. However, such host response may be 
beneficial to protecting the long-term survival of transplanted cells. Also, similar functional rescuing 
results could be obtained from chromaffin cells attached to dextran-based microcarriers or glass bead 
microcarriers [173]. This suggests that transplanted cell survival was more related to the provision of 
attachment by the microcarriers than biomaterial used. 
Poly(hydroxybutyrate) (PHB) 
PHB is produced naturally by certain species of bacteria and can be degraded by the same 
mechanics as the synthetic polyesters mentioned in Section 4.2.1 [4]. PHB has been applied as a  
cell-carrying NGC (Table 4E). PHB conduits with SCs were able to promote neuroregeneration in a  
10 mm sciatic nerve gap in rats [176]. When alginate, fibronectin and SCs were added to a PHB 
conduit, these conduit-filling components presented an additive effect on axonal regeneration as well 
as survival and proliferation SCs [151]. However, the application of PHB is hindered by concerns over 
contamination from bacteria components [3]. 
This section presented common biomaterial candidates for temporary to long-term cell and  
growth factor delivery. Although most of combinatory therapies with cells and biomaterials are still  
in preclinical development, they offered promising opportunities for repair and regenerating the  
nervous system. 
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Table 4. Examples of non-animal derived natural biomaterials as cell-carriers applied in animal or clinical trials. 
Biomaterial Form of Scaffold 
Cells & Modified Factor 
Expression (if any) 
Animal & Neurological 
Disorder Model 
Outcomes Ref. 
(A) Alginate 
Microcapsule CNS  
- 
Fibroblast-endostatin Rat glioma model 
Supported transplanted cell survival, sustained 
factor delivery and reduced tumor volume. 
Animals survived longer. 
[166] 
Myoblast-CNTF 
Mouse AD model  
(amyloid-β oligomer-induced) 
Supported transplanted cell survival and 
improved cognitive function. 
[158] 
MSC-GLP-1 
Rat TBI model  
(controlled cortical impact) 
Supported transplanted cell survival and exerted 
neuroprotective effects. 
[163] 
With polylysine or 
polyornithine coating 
CP cell 
i. Rat stroke model  
(MCAO induced)  
ii. Rat and non-human primate 
HD model (QA induced)  
iv. Cat deaf model 
(aminoglycoside induced) 
Supported transplanted cell survival. Reduced 
striatal infarct or lesion volume and improved in 
motor and neurological functions. Auditory 
neuron rescue most prominent when combined 
with chronic electrical stimulation. 
[70,159,161,164,165] 
Chromaffin cell 
Rat PD model  
(6-OHDA induced) 
Supported transplanted cell survival and 
reduced rotational behavior. 
[162] 
PC12 
Rat chronic pain model  
(Chronic constriction induced) 
Supported transplanted cell survival and 
suppressed cold allodynic behavior. 
[167] 
SC-BDNF 
Guinea Pig deaf model  
(ototoxin induced) 
Enhanced auditory neuron survival. [168] 
Filler of Tubular NGC PNS  
Of PHB conduit, 
with fibronectin in 
alginate gel 
SC Rat sciatic nerve gap (10 mm) 
Improved transplanted cell survival. Supported 
proliferation of transplanted SCs and host SCs. 
.Augmented axonal regeneration. 
[151] 
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Table 4. Cont. 
Biomaterial Form of Scaffold 
Cells & Modified Factor 
Expression (if any) 
Animal & Neurological 
Disorder Model 
Outcomes Ref. 
(A) Alginate 
Filler of cell-encapsulating device CNS  
Of P(AN/VC) Chromaffin cell 
Phase I clinical trial: Chronic 
pain patients 
Devices were retrievable. Supported 
transplanted cell survival without 
immunosuppressant. Yet, only moderate 
therapeutic outcomes, including morphine 
intake and pain ratings improvements, were 
detected in some patients. 
[23] 
(B) Agarose 
Coating of electrode CNS  
- Fibroblast-BDNF 
Guinea pig deaf model 
(kanamycin and  
ethacrynic acid induced) 
Despite decreasing cell survival over 
implantation period, device exerted 
neuroprotection on spiral ganglion neurons. 
[169] 
(C) Chitosan 
Tubular NGC PNS  
With collagen and 
NGF 
NSC 
Rabbit facial nerve defect  
(10 mm) 
Increased axonal regeneration. [171] 
With Matrigel® SC Rat sciatic nerve defect (12 mm) 
Improved axonal regeneration, nerve conduction 
velocity and mid-shank circumference. 
[154] 
Of chitosan conduit, 
with PLGA fiber 
inserts 
MSC 
Canine sciatic nerve defect  
(60 mm) 
Improved axonal regeneration  
and functional recovery. 
[122] 
MSC 
Non-human primate median 
nerve defect (50 mm) 
Improved axonal regeneration  
and functional recovery. 
[123] 
With multi-
channeled conduits 
MSC Rat sciatic nerve defect (8 mm) 
Improved axonal regeneration. SFI recovery 
comparable to autograft. 
[42] 
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Table 4. Cont. 
Biomaterial Form of Scaffold 
Cells & Modified Factor 
Expression (if any) 
Animal & Neurological 
Disorder Model 
Outcomes Ref. 
(C) Chitosan 
Scaffold  PNS  
Of chitosan-silk 
fibroin 
Adipose-derived stem cell  
or SC 
Rat partial sciatic nerve defect 
(10 mm) 
Improved axonal regeneration, gastrocnemius 
muscle mass and SFI recovery. 
[170] 
Of silicone, with 
laminin-coated  
multi-walled  
chitosan insert 
MSC Rat sciatic nerve gap (10 mm) 
Improved axonal regeneration, ameliorated loss 
of gastrocnemius muscle mass and enhanced 
SFI recovery. 
[80] 
(D) Dextran 
Microcarrier CNS  
With collagen 
coating Cytodex® 3 
(Sigma-Aldrich) 
Chromaffin cell 
Rat PD model  
(6-OHDA induced) 
Supported transplanted cell survival, reduced 
lesion volume and sustained improvements in 
rotational behavior and motor functions 
[173,174] 
(E) PHB 
Tubular NGC PNS  
- SC Rat sciatic nerve gap (10 mm) Improved axonal regeneration. [176] 
With fibronectin in 
alginate gel matrix 
SC Rat sciatic nerve gap (10 mm) 
Improved transplanted cell survival. Supported 
proliferation of transplanted SCs and host SCs. 
Augmented axonal regeneration. 
[151] 
With fibrin SC & differentiated MSC Rat sciatic nerve defect (10 mm) Improved nerve regeneration distance. [152] 
Abbreviations: AD: Alzheimer’s disease, BDNF: brain-derived neurotrophic factor, CNS: central nervous systems, CNTF: ciliary neurotrophic factor, CP cell: choroid 
plexus cell, GLP-1: Glucagon-like peptide-1, HD: Huntingdon’s disease, MCAO: middle cerebral artery occlusion, MSC: bone marrow mesenchymal stem cell,  
NGC: nerve guidance channel, NGF: nerve growth factor, NSC: neural stem cell, P(AN/VC) poly(acrylonitrile-co-vinyl chloride), PC12: pheochromocytoma cell,  
PD: Parkinson’s disease, PHB: poly(hydroxybutyrate), PLGA: poly(lactic-co-glycolic acid), PNS: peripheral nervous system, QA: quinolinic acid, SC: Schwann cell,  
SFI: sciatic function index, TBI: traumatic brain injury, 6-OHDA: 6-hydroxydopamine. 
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5. Conclusions and Future Perspectives 
To date, full functional regeneration of the human nervous system remains a challenge, especially 
for injuries of the CNS and critical sized gaps in the PNS. Increasing knowledge in the characteristics 
and properties of different cell and biomaterial candidates as well as their interactions with the host 
microenvironment takes us one step closer to achieving this goal. In this review, we have focused on 
the most common non-biodegradable and biodegradable scaffolding materials for conveying cells to 
targeted sites for prolonged neuroactive factor delivery as well as cell replacement. Non-biodegradable 
cell-encapsulating systems have been shown to be well tolerated in vivo and retrievable after 
prolonged implantation in clinical trials. These systems are promising in providing a continuous drug 
delivery at the site of injury or tissue loss. However, these materials have limited ability in promoting 
neuroregeneration. As for biodegradable materials, due to their tunable mechanical, biochemical and 
degradation properties, they can be applied as long-term cell encapsulation drug delivery or culturing 
device, and also temporary scaffolds for protecting transplanted cells and mechanically supporting 
injured tissue. However, synthetic biodegradable materials do not have the inherited bioactivity as in 
natural materials, whereas for natural materials, reaction and degradation rates are often more difficult 
to control when compared with synthetic materials. To maximize the merits of different types of 
scaffolding materials, hybrid scaffolds and scaffold functionalization with physical, biochemical and 
electrical cues can be applied. These modifications allow researchers to have a more precise control 
over cell-material interactions and to manipulate the spatial and temporal events during 
neuroregeneration more effectively. The combined strategies can potentially target multiple aspects of 
the neurological disorder. 
Although many innovative and promising cell-conveying scaffolds have been developed, some 
issues have to be addressed before they can be applied in clinical settings. As these scaffolds are meant 
for extended applications, more data is needed regarding the long-term performance of the implant 
system. This includes safety, sustainability and controllability of factor release, well-regulated cell 
survival, growth, differentiation, migration and tissue re-organization, as well as therapeutic efficacy 
and long-term interactions with other living components in animal and clinical studies. Additional 
factors to consider are tunable properties for individualized applications in addition to consistency and 
ease of scaling up in manufacturing process. 
Better understanding of injury progression mechanisms in terms of anatomical and physiological 
changes on top of the effectiveness of different neuroactive drug and cell candidates is essential for 
developing the next generation of cell-carrying scaffolds. This allows researchers to tailor conveyer 
systems that encourage more dynamic interactions with the transplanted cells and host tissue at various 
stages of regeneration. Multiple-component and multiphasic scaffolds can be developed to provide a 
more precise spatial and temporal control over cell behavior and function, such as differentiation and 
migration, and tissue restructuring. With the combination of different biomaterials, cells, instructive 
physical, biochemical and electrical cues, therapeutic potential of cell-based polymer scaffolds can be 
further amplified. As these systems involve more components, more complex analysis will be required 
to fully characterize them. 
In conclusion, the integration of biomaterial scaffolds and cell-based therapies have great potentials 
in promoting functional repair and structural regeneration in the human nervous system. 
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